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ABSTRACT 
Among the distinct routes of drug administration (e.g. oral, parenteral, transdermal, 
mucosal), the oral route is the most convenient and promising one, due to its non-
invasiveness, ease of administration, versatility of dosage forms and the higher levels of 
patient compliance. Nonetheless, this route of drug delivery poses some limitations, such as 
low retention times in the stomach, first pass metabolism in the liver, solubility of the drug in 
gastrointestinal fluids, drug permeability across biological membranes and poor control over 
drug release that may hinder oral bioavailability of the drugs.  
This monograph focus on emerging trends in pharmaceutical dosage forms that are being 
developed to address some of these limitations.  
The following dosage forms are discussed: Gastroretentive Floating Drug Delivery Systems, 
Medicated Chewing Gums, Pulsatile Drug Delivery Systems and Self-Microemulsifying Drug 
Delivery Systems. 
For each one it is clarified the state of the art, the advantages and limitations, the parameters 
for evaluation of performance, the products available on the market and the regulatory 
considerations. 
 
Keywords: New Drug Delivery Systems, Oral route, Bioavailability Enhancement, Patient 
Compliance, Gastroretentive Floating Drug Delivery Systems, Medicated Chewing Gums, 
Pulsatile Drug Delivery Systems, Self-Microemulsifying Drug Delivery Systems.  
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1.1. Pharmaceutical Contextualization 
Since ancient times, human civilization is focused on finding medicines that can reach 
human’s needs, concerning every single aspect of life and health (1). For thousands of years, 
drugs were based on natural resources with lack of scientific reasoning on the molecular 
structure of the drug substance (DS) that is responsible for the therapeutic effect (1, 2). The 
use of natural extracts was responsible for soothe or eradicate some diseases or symptoms 
(2), and medicine was practiced through observation and empiricism (1). 
Nevertheless, it was only by the 19th Century that the pharmaceutical industry came up with 
more systematic and scientific practices (1). The constant growing of knowledge in terms of 
chemistry and biology came up through the 20th Century along with a technological 
revolution that provided more precise techniques of screening and evaluation (1 – 3). That 
allowed a better molecular control of the drugs that were manufactured and a better 
understanding on what was behind the pharmacological effect of those raw materials found 
in nature (2). Some of these drug exhibit pharmacological properties that are still recognized 
in the present times (1). After that, science progressed to a point at which large scale 
production of synthetic drug candidates proved to be economically feasible (2).  
Two matchless achievements of pharmaceutical industry were the launch of Aspirin® by 
Bayer in late 19th Century and the commercialization of penicillin at the end of the Second 
World War, leading to a pharmacological explosion (3).  
 
1.2. New Drug Delivery Systems 
Over the years, pharmaceutical companies and scientists have been making efforts to find 
optimal drug delivery systems centered on patients’ needs (5), in order to increase patient 
compliance and acceptability (4). Scientific developments had provided viable dosage 
alternatives that can be administered via different routes, such as oral, parenteral, 
transdermal, and mucosal (4). Among all routes of drug administration available, the oral 
route is the most convenient and promising delivery system (4 – 6), due to its non-
invasiveness, ease of administration, versatility of dosage forms, relatively low cost of therapy 
and the higher levels of patient compliance (4 – 6). Around 50% of the available medicines in 
the market consist in oral drug delivery systems (6). Although there are many advantages in 
the oral delivery, there are some limitations that may hinder the oral bioavailability of the 
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drug substances. Those limitations include low retention times of the drug in the stomach, 
the hepatic first pass metabolism, solubility of the drug in gastrointestinal fluids, its 
permeability across biological membranes (5) and the poor control over release of the drug 
along with its potential side effects (4).  
During the last decades efforts have been made to develop novel and more efficient oral 
drug delivery systems able to overcome the limitations of this route of drug administration, 
by releasing the drug after a predetermined time, in a predetermined place and at a 
controlled rate in a single dose (6).  
One challenge in oral drug delivery is to increase the retention times in the gastrointestinal 
tract (GIT) and also to overcome the unpredictable gastric emptying rates (4, 7). 
Gastroretentive Drug Delivery Systems (GRDDS) are a good approximation to achieve that 
purpose (4, 7). Many approaches have been exploited for the development of GRDDS, such 
as floating systems, high-density systems, low-density systems, expandable systems, super 
porous hydrogel systems and mucoadhesive systems (4, 7). Among those, Floating Drug 
Delivery Systems (FDDS) will be discussed in this monograph. Those systems show a density 
lower of that of gastric fluids, thus remaining buoyant over the gastric contents while 
releasing the drug substance, without affecting the gastric emptying rate for a prolonged 
period (7). As a consequence, the drug shows higher bioavailability, being FDDS more 
advantageous for drugs absorbed in the upper parts of the GIT (7).   
Medicated Chewing Gums (MCG) are a novel approach of drug delivery that is intended to 
be chewed but not swallowed, while the drug is slowly released in the oral cavity (8). The 
drug substance is meant to act locally in mouth diseases or to be directly absorbed into the 
systemic circulation by the jugular vein, thus allowing to overcome the first pass metabolism 
in the liver (8). Besides that, these drug delivery systems are advantageous because high 
plasma peak concentrations are avoided, reducing side effects of drugs (8). A great advantage 
of MCG, that increases patient compliance, is the possibility of a discrete administration 
without water (8).  
Pulsatile Drug Delivery Systems (PDDS) are another type of dosage form addressed in this 
monograph. This drug delivery system is developed with an intimate connection to 
chronotherapeutics views, since some diseases display circadian variations of their symptoms 
(9, 10). PDDS allow to deliver the right dose of the drug at a specific time and in a specific 
local, providing spatial and temporal delivery (9, 10). This property results in an optimized 
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efficacy of the drug and a minimization of the side effects (9, 10). The drug release profiles 
are characterized by two phases: a lag time of no drug release, followed by a complete 
release within a short period of time (9, 10).   
A high percentage of the new drug candidates are lipid drug substances, thus having poor 
water solubility and influences their oral bioavailability (5). This had turned attentions to 
dosage forms capable of delivering lipid drugs at reasonable rate and extent of oral 
bioavailability (5). In this monograph special attention is given to Self-Microemulsifying Drug 
Delivery Systems (SMEDDS) and to their solid forms, Solid Self-Microemulsifying Drug 
Delivery Systems (S-SMEDDS). These drug delivery systems consist on mixtures of oil, 
surfactant, co-surfactant and drug substance, which spontaneously form transparent oil-in-
water microemulsions upon contact with the aqueous medium of GIT and its motility (11). 
They have the advantages of presenting the drug substances in dissolved form by forming 
microemulsions with a droplet size of less than 50 nm, thus providing a large interfacial 
surface area for drug absorption (11). 
 
1.3. Gastrointestinal Tract Anatomy and Physiology 
The gastrointestinal tract consists on a tube of about seven meters long that includes the 
oral cavity, esophagus, stomach, small intestine and large intestine (12). The anatomical and 
physiological parameters of the GIT are depicted in Table 1.1. As it is possible to conclude, 
parameters such as anatomy, absorption characteristics, pH and microbial environment vary 
significantly along the distinct sections of the GIT (12, 13).  
 
1.3.1. Oral Mucosa 
The anatomy and physiology of oral cavity has been extensively reviewed (12). The oral 
cavity is composed by cheeks, hard and soft palates and tongue (see Fig. 1.1).  The oral 
mucosa is relatively permeable and has a rich blood supply (16, 17), and microscopically can 
be subdivided in three layers as depicted in Fig. 1.2:  
- Oral epithelium 
- Lamina propria 
- Sub-mucosa 
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Table 1.1. Parameters of the various segments of the gastrointestinal tract. 
The oral epithelium consists on a stratified squamous epithelium having a thickness of 
around 40 – 50 cell layers and a turnover time of around 5 – 6 days (16). The epithelium is 
mainly non-keratinized, but it is keratinized in areas subjected to mechanical stress such as 
gingivae and hard palate, which are relatively impermeable to water, in contrast with 
keratinized epithelia (16). Lamina propria and sub-mucosa are connective tissues (12).  
The permeability of the oral mucosa is variable along the distinct regions of the oral cavity 
(16, 17), being measured by the permeability coefficient (17). This coefficient is a measure of 
how easily the drug can permeate a membrane (17), and is based on the relative thickness 
and degree of keratinization of the distinct tissues (16, 17), and the physicochemical 
properties of the drug (17). Thus, non-keratinized tissues show higher permeability, as well 
as thinner tissues.  
 Parameters 
Section 
Average 
Length (cm) 
(13, 14) 
Absorbing 
surface area 
(m2) (13, 15) 
Villi Present (12, 
14) 
Transit time 
of food (h) 
(14) 
pH (14) 
Microorganism 
(counts/g)2 
(15) 
Oral 
Cavity 
15 – 20 – Absent Short 5.2 – 6.8 – 
Esophagus 25 – Absent Very short 5 – 6 – 
Stomach 20 0.1 Scarcely present 0.25 – 3.00 1.3 – 3.5 102 
Small 
Intestine 
350 – 700 120 – 200 – – – – 
Duodenum 30 0.1 Scarcely present 1.00 – 2.00 4.6 – 6.0 102 
Jejunum 300 60 Abundantly present – 6.3 – 7.3 105 
Ileum 400 60 Abundantly present 1.00 – 10.00 7.6 107 
Large 
Intestine 
90 – 150 0.35 – – – – 
Cecum 10 – 30 0.05 Scarcely present Short 7.5 – 8.0 1011 
Colon 150 0.25 Absent 4 – 20 7.9 – 8.0 1011 
Rectum 15 – 19 – Absent Variable 7.5 – 8.0 – 
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Figure 1.1. Schematic representation of oral cavity anatomy (12). 
Lamina Propria 
Submucosa 
Oral Epithelium 
Basement Membrane 
Figure 1.2. Schematic representation of the oral mucosa. Adapted from 16. 
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1.3.2. Stomach 
The stomach is anatomically divided into four regions: cardia, fundus, body and antrum 
(pylorus) (12), see Fig. 1.3. It is a J-shaped expandable portion of the GIT located between 
the esophagus and the small intestine (12). It has the main functions of acting as a mixing 
chamber, as a reservoir of ingested food, and performs digestion of the meal contents to a 
liquid called chyme (12, 18). The digestion is both mechanical with aid of muscular 
contractions and chemical with aid of secretions (12). Then the chyme is forced through the 
pylorus into the duodenum at controlled slow rate in a phenomenon called gastric emptying 
(12, 18).  
Figure 1.4. Schematic representation of Human gastrointestinal tract histology. Adapted from 12. 
Figure 1.3. Schematic representation of Human stomach. Adapted from 12. 
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Histologically the wall of the stomach is similar to the other parts of the GIT (Fig. 1.4), 
except for the presence of an additional oblique layer of smooth muscle in the muscularis 
(12). In the fasted state, the stomach is empty and the mucosa lies in distinct large folds 
called rugae (Fig. 1.3).  
 
1.3.3. Gastric Emptying  
Gastric emptying takes place in both fasted and fed states, with distinct motility patterns in 
each state (14).  During the fasted state a series of electrical events takes place between the  
stomach and the intestine every 2 – 3 hours, which is commonly called migrating myoelectric 
complex (MMC). The MMC is divided into the following 4 phases (14), see Fig. 1.5:  
- Phase I (basal phase) is a quiescent period that lasts for 30 – 60 minutes with rare 
contractions.  
- Phase II (pre-burst phase) lasts for 20 – 40 minutes and registers intermittent action 
potential and contractions, with gradual increase of intensity and frequency.   
- Phase III (burst phase) lasts for 10 – 20 minutes and includes the housekeeper waves, 
which are intense and regular contractions for short period. It is responsible for 
sweep off the undigested materials from the stomach.  
- Phase IV (transition phase) lasts for 0 – 5 minutes and is the transition period 
between phases III and I of two consecutive cycles.   
After the ingestion of food, the pattern of contractions changes from fasted to that of fed 
state which is characterized by a continuous pattern of spike potentials and contractions, 
called postprandial motility (14).  
Figure 1.5. MMC and motility patterns of the GIT in the fasted state (14).  
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1.3.4. Gastric pH  
The gastric pH is variable and may be influenced by many factors such as diet and feeding 
state (19), age (20), drugs and pathological conditions (21), all along with the intra and 
intersubject variations (19 – 23). It is reported that the mean value of gastric pH in fasted 
healthy volunteers is around 1.3 (20), due to the strong acidic secretions in the stomach 
(12), a value that raises approximately three units when a meal is administered (20). The pH 
in the duodenum rises when compared to the pH in the stomach. This is due to the 
secretion of bicarbonate by the pancreas (pH 7.1 – 8.2) that buffers the acidic chyme 
peristalted from the stomach (12). Along the small intestine the pH rises up to a value 
around 7.4 (23) and maintains a basic range of pH values in the large intestine.  
 
1.4. Aim Of The Monograph 
The main objective of this monograph is to discuss the state-of-art of novel pharmaceutical 
drug delivery systems that were developed in order to overcome some of the limitations of 
conventional dosage forms. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
2. CHAPTER I 
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Figure 2.1. Different approaches to develop gastroretentive drug delivery systems (24, 25).  
2.1. Gastroretentive Drug Delivery Systems 
Physiological characteristics concerning short gastric residence time and unpredictable 
gastric emptying rates are a limiting issue that has to be taken into account when developing 
a suitable delivery system (24). Having this in mind, several attempts have been made to 
develop dosage forms capable of increasing the gastric residence time, leading to an increase 
of the oral bioavailability, to reduced chances of dose dumping and to enhance the solubility 
of drugs that are less soluble in high pH environments (25). Gastroretentive Drug Delivery 
Systems are an approach to reach this goal, since they are intended to be retained in the 
stomach for a prolonged time, for improving the therapeutic outcome of the drug substance 
(24, 25).  
Investigation in academia and industry has been driven in distinct ways in order to achieve 
the better approach to prolong gastric residence time of drug delivery systems (25). In the 
present time several are the approaches to gastric retention found in literature, see Fig. 2.1. 
Besides that there are few Gastroretentive drug delivery systems available in the market 
(25). In this monograph it will be given special attention to a subtype of these dosage forms, 
the Floating Drug Delivery Systems (FDDS) which is one of the most frequent approaches 
studied, due to the absence of any adverse effect on the motility of GIT. Moreover, these 
novel dosage forms may be manufactured using conventional equipment (24). Those systems 
are intended to achieve a buoyancy state when in contact with gastric contents, taking 
advantage of the relative density between the drug delivery system and the gastric 
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fluids (25). In this way it is possible to prolong the gastric residence time of the drug, thus 
increasing oral bioavailability without compromising the gastric emptying rate (24, 25).   
 
2.2. Floating Drug Delivery Systems 
Floating Drug Delivery Systems captured the attention of researchers and companies since 
the late 60’s, after floating system was first described in 1968 by Davis (26). These are low-
density systems designed to be retained in the stomach and to prolong the gastric residence 
time, delivering the drug slowly and in a desired rate, thus contributing to an enhancement 
of absorptive capacity of drug substances and consequently greater oral bioavailability (27). 
This is achieved by enabling a buoyant state, which is the capacity of the dosage form to float 
above gastric contents without compromising gastric emptying rate (25), of the dosage form 
in the stomach (27). To reach that state, a system with a density smaller than the density of 
gastric fluids may be achieved (27). As a matter of fact, those systems must have three main 
characteristics in the stomach: have a bulk density of less than 1 g.cm-3, maintain its 
structural integrity and finally, the release of the drug should be constant, without affecting 
the gastric emptying rate (28). They are also eliminated when all the drug substance is 
released (25, 28). To achieve this buoyancy state different excipients have been investigated 
and will be referenced forward in this chapter.  
When designing floating dosage forms it is of crucial importance to consider the factors 
affecting their buoyancy state, namely factors concerning the formulation parameters and the 
patient related variabilities (27, 28). It is also very important to have fundamental knowledge 
in anatomy and physiology of the GIT and to understand the process of gastric emptying 
(Introduction sections 1.3.2. – 1.3.4.), because they may affect FDDS efficacy (24). The 
floating formulation is intended to remain in the upper part of the stomach so that undesired 
gastric emptying can be more efficiently avoided. This makes the floating lag time, i.e., the 
time that the dosage form takes to float in the stomach after contact with gastric contents, a 
crucial variable to control (28, 29). Floating lag time has a relation of inverse proportionality 
with efficacy (29): the lower the time to achieve buoyancy state, the less the probability for 
dose dumping, enhancing the safety and the efficiency of the dosage form.   
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2.2.1. Classification and Manufacturing Processes 
Floating Drug Delivery Systems can be classified in three categories, as shown in Fig. 2.1, 
according to the mechanism of buoyancy (30 – 32) taking into account that single and 
multiple unit systems can be both formulated: 
I. Effervescent Systems 
II. Non-effervescent Systems 
III. Raft Forming Systems 
It is important to retain the idea that single unit systems consist of an individual particle, 
while multiple unit systems consist on a conjugation of a large number of small sized 
particles, being developed as hollow microspheres (microballoons), granules, mini-tablets or 
pellets (28). It is more challenging to develop multiple unit systems and it usually requires 
more specialized equipment. In spite of that, multiple unit systems have advantages over 
single unit systems such as reduction of the risk of dose dumping by avoidance of all-or-none 
gastric emptying of the dosage form, uniform release of the drug substance and reduction of 
intra and intervariability in absorption (32, 33). These advantages allow an enhancement of 
the absorption efficacy (32). 
 
I. Effervescent Systems 
Effervescent systems remain buoyant due to their low density as a result of gas generation 
and entrapment inside the dosage form (28). These systems include matrices with swellable 
polymers such as methylcellulose, hydroxypropylmethyl cellulose (HPMC) and chitosan 
based polymers, effervescent agents, which include gas generating agents such as carbonates 
and bicarbonates (e.g. sodium bicarbonate) and organic acids such as citric and tartaric acid, 
or chambers containing a liquid, such as ether or cyclopentane, that gasifies at body 
temperature (37 ºC) (27, 28, 30, 34). This makes effervescent systems able to be classified in 
two categories, according to the formulation type: 
A. Gas Generating Systems 
These systems are formulated in a way that when in contact with acidic gastric fluids, carbon 
dioxide, CO2, is generated and remains entrapped inside the dosage form (Fig. 2.2A) (28, 
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34). This in situ CO2 generation is responsible for the buoyancy state of the dosage form, 
since density decreases below 1 g.cm-3, and is a result of the reaction between gas generating 
agents and the organic acids present in the formulation, empowered by the absorption of 
water by the dosage form (27, 30).  
Intra Gastric Single Layer Floating Tablets or Hydrodynamically Balanced System (HBS). The basic 
principle behind the formulation of these systems is to develop a matrix consisting of an 
intimate mix of the drug substance and CO2 generating agents (Fig. 2.3). When these type of 
tablet dosage forms (27) contact with gastric fluids, an effervescent reaction occurs. This 
leads to the generation of a gas that is entrapped in a jellified hydrocolloid layer of the 
system (Fig. 2.4A). Alternatively, it is also possible to develop capsular dosage forms (28) 
based on a similar mechanism: the drug is mixed with gel-forming hydrocolloids encapsulated 
 
Figure 2.2.  Schematic diagram of Intragastric Single Layer Drug Delivery Systems manufacturing 
process: (A) tablet dosage forms and (B) capsular dosage forms (35). 
A 
B 
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Tablet Capsule 
Figure2.3. Schematic diagram of Intragastric Single Layer Drug Delivery Systems manufacturing 
process: (A) tablet dosage forms and (B) capsular dosage forms (35). 
Figure 2.4. Formulation and mechanism of action of Intragastric Single Layer Drug Delivery 
Systems, (A) in tablet dosage forms (27) and (B) in capsular dosage forms. Adapted from 28. 
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in a soluble capsule shell. After administration, the capsule shell dissolves and its interior is 
exposed to the gastric fluids (28). Then the hydrophilic polymers swell to form a gelatinous 
barrier which is responsible for the buoyancy state (Fig 2.4B). In both cases the drug is 
released by diffusion and erosion of the gel barrier.  
Intra Gastric Bilayer Floating Tablets. These tablets are similar to those previously described 
but with the particularity of containing two layers (27): a first layer, which immediately 
releases an initial dose of the drug for the system, and a second layer that absorbs gastric 
fluids, forming a colloidal gel barrier on its surface that releases the drug in a sustained way 
(Fig. 2.5). The manufacturing process is identical to that of intra gastric single layered tablets, 
but includes an additional step: when the single layer floating tablet is developed, a second 
compression takes place to add the immediate release layer (36, 37). This step makes the 
process more complex (36, 37). All bibliographic sources consulted refer to the use a single 
punch compression machine for the second compression. 
Multiple Unit Type Floating Pills. The concept sustaining this multiple unit floating dosage form 
is the development of sustained release pills as seeds surrounded by double layers (Fig. 2.6), 
which float as a consequence of CO2 generation (29), showing a buoyant behavior as 
described in Fig. 2.2A. While the inner layer includes the effervescent agents, such as sodium 
bicarbonate and tartaric acid, being segmented in two sub layers in order to avoid direct 
 
Figure 2.5. Formulation and mechanism of action of Intragastric Bilayer Drug Delivery Systems 
(27). 
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Figure 2.6. Formulation of multiple unit floating pills as seeds (29). 
 
contact between distinct effervescent excipients (29), the outer layer includes swellable 
polymers, such as polyvinyl alcohol (PVA) and shellac (30, 34). Once in contact with the 
dissolution medium at body temperature, the system sinks in the solution. At that point, the 
solution permeates into the effervescent layer through the swellable layer (29). 
Consequently, gas generation by the neutralization reaction between the two effervescent 
excipients in the dosage form takes place, allowing the buoyant state and forming swollen 
pills like balloons (27, 29). These delivery systems are able to be designed by multiple coating 
of non pareil seeds in a fluid bed granulator (38), as described in Fig. 2.7, and may be further 
inserted into capsules (by capsule filling) or converted to tablets (by powder direct 
compression) containing a variable number of these pills (39).  
 
B. Volatile Liquid/Vacuum Containing System  
This formulation consists of a matrix containing a chamber or a reservoir that inflates in the 
acidic environment of the stomach, allowing the flotation of the dosage form (34). Distinct 
approaches are possible to be developed, as referred in literature, and are described below. 
Inflatable Gastrointestinal Drug Delivery System. These systems consist on a biodegradable 
gelatin capsule filled with an inflatable chamber in a drug reservoir that can be a drug 
impregnated polymeric matrix (Fig. 2.8). The inflatable chamber incorporates liquid ether 
that gasifies at body temperature. It is the process of forming a gas that is responsible for the 
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 fluids the capsule disintegrates to release the drug reservoir together with the inflatable 
chamber (27). As a consequence, the chamber inflates allowing drug reservoir to be retained 
in the stomach while releasing the drug continuously into the stomach (27). After the drug 
release the system leaves the stomach. It was not possible to find any information regarding 
the manufacturing process of such drug delivery systems.  
 
Intra Gastric Osmotically Controlled Drug Delivery System. This system consists on an intragastric 
osmotically controlled drug delivery device, comprising an inflatable floating support and an 
osmotic pressure controlled drug delivery device, loaded in a biodegradable capsule (Fig. 
2.9). The inflatable floating support contains a biodegradable plug that erodes after a 
predetermined time in order to deflate the support (27). The osmotic pressure controlled 
drug delivery device consists of two components: a) a drug reservoir compartment, which is 
enclosed by a pressure responsive collapsible bag impermeable to liquid and vapor and has a 
drug delivery office, and b) an osmotically active compartment, which is enclosed within a 
semipermeable housing and contains an osmotically active salt (29). After oral administration 
the dosage form enters the stomach and contact with gastric fluids. At this moment, the 
capsule disintegrates and releases the intragastric osmotically controlled drug delivery device 
(27). Then the inflatable chamber forms a hollow polymeric bag that contains a liquid, such 
as ether or cyclopentane that gasifies at physiological temperature to produce a gas, being 
responsible for the floating behavior of the dosage form (27). The water in the gastric fluids 
is then absorbed through the semipermeable membrane into the osmotically active 
compartment and dissolves the osmotically active salt (27). This process creates an osmotic 
pressure that acts in the collapsible bag and forces the drug reservoir compartment to 
reduce its volume (27). Then it releases the drug solution formulation into the gastric 
environment through the delivery orifice, enhancing its bioavailability (27). After a 
predetermined time, the vapor escapes from the device and the deflated drug delivery 
system is emptied from the stomach (27, 29). Again, it was not possible to find any 
information regarding the manufacturing process of such drug delivery systems.  
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II. Non-Effervescent Systems 
Floating non-effervescent dosage forms are based on a mechanism of swelling of polymers 
due to their soaking and capacity to absorb water, when in contact with gastric fluids after 
oral administration (29, 30, 32 – 34). As a consequence they remain buoyant and are 
retained in the stomach while releasing the drug substance. The most commonly used 
polymers are gel forming or highly swellable cellulosic type hydrocolloids (e.g. hydroxyl ethyl 
cellulose (EC), HPMC and sodium carboxymethyl cellulose), polysaccharides and matrix 
forming polymers (e.g. polycarbonates, polyacrylates and polystyrene) (29, 30, 32 – 34, 36) 
Figure 2.8. Inflatable Gastrointestinal Drug Delivery System. Adapted from 27. 
Figure 2.9. Intragastric Osmotically Controlled Drug Delivery System (29). 
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as well as bioadhesive polymers such as chitosan and carbopol (34). Those excipients are 
incorporated in high level, from 20 to 75% w/w, in tablets and capsules (32). The general 
mechanism of floating of swellable non-effervescent systems is described in Fig 2.2B.  
Floating non-effervescent systems are able to be developed as tablets and capsules, and also 
as multiple unit system approaches, such as alginate beads or hollow microspheres (29). 
Single Layer Floating Tablets/Colloidal Gel Barrier Systems. The formulation of this dosage form 
consists on the intimate mix of the desired drug substance with the gel-forming hydrocolloid 
(27, 34). The system maintains a bulk density lower than 1 g.cm-3 due to the air entrapped in 
the swollen polymer after contact with gastric fluids, allowing the dosage form to remain 
buoyant (27, 34). The gel barrier formed after contact with water controls the rate of fluid 
penetration and consequent release of the drug substance (34). Visually this dosage form is 
identical to Fig. 2.4A in case of tablets, and Fig. 2.4B in case of capsules, and the 
manufacturing process is identical to that of HBS (Fig. 2.3) with the excipient differences.  
Bilayer Floating Tablets. These systems contain two distinct layers with two distinct functions. 
The immediate release layer is responsible for the release of an initial dose of the drug from 
the system (27). On the other hand, the sustained release layer absorbs gastric fluids, 
consequently forming an impermeable colloidal gel barrier on its surface (27). This allows the 
system to remain buoyant in the stomach with a density lower than 1 g.cm-3. Visually this 
dosage form is identical to Fig. 2.5 and the manufacturing process is also identical to that of 
intra gastric bilayer tablets, except for the differences in the excipients used in the 
formulation.  
Microporous Compartment Systems. The formulation of this dosage form consists on the 
encapsulation of a drug reservoir inside a microporous compartment, as depicted in Fig. 
2.10, whose top and bottom walls show apertures that allow water penetration to dissolve 
the drug and to make it available for absorption (34). Having the peripheral walls completely 
sealed it is crucial to prevent contact between undissolved drug and gastric mucosa (34). 
The flotation chamber containing entrapped air is responsible for dosage form floating 
behavior in stomach. It was not possible to find any information regarding the manufacturing 
process of such drug delivery systems.  
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Floating Beads/Alginate Beads. Alginate beads are floating multiple unit systems (27). Most of 
literature works and reviews describe alginate beads prepared by the freeze drying method 
(40). Spherical floating beads of 2.5 mm in diameter are obtained by dropping a sodium 
alginate solution into aqueous calcium chloride, leading to the precipitation of calcium 
alginate (40). The beads are then separated, snap-freezed with liquid nitrogen before being 
freeze-dried at -40ºC for 24 hours (40). The result is a porous system which remains 
buoyant in the stomach for over 12 hours and has a prolonged gastric residence time of 
more than 5.5 hours (40). But the method used for production of alginate beads is not 
suitable for application in conventional pharmaceutical companies, since it requires 
sophisticated specific equipment or conditions usually not available. 
Hollow Microspheres. Hollow microspheres, also called microballoons, are multiple unit 
systems of floating dosage forms able to float over gastric contents (41). This type of FDDS 
consists of low-density spherical porous empty particles without core (Fig. 2.11), having a 
size less than 200 µm and the drug dissolved or dispersed throughout the particle matrix 
(41). When in contact with gastric fluids, the polymers (such as chitosan, Eudragit, 
polycarbonates and others) of the formulation hydrate and form a colloidal gel barrier that 
controls fluid penetration and consequent drug release (41). Hollow microspheres are 
commonly prepared by solvent diffusion and evaporation method, as described in Fig. 2.12, 
to create the hollow inner core (33). In this method the polymer is dissolved in an organic 
solvent and the drug is dissolved or dispersed in the polymer solution (41). Then, the 
solution containing the drug is emulsified into an aqueous phase containing PVA to form 
stable oil in water (o/w) emulsions (41). Then the organic solvent is evaporated by increasing 
Figure 2.10. Microporous Compartment System (30). 
2. Chapter 1. Gastroretentive Drug Delivery Systems 
 
24 
 
 
the temperature under pressure or by continuous stirring (41). This leads to 
polymerprecipitation at the o/w interface of droplets, forming a cavity and thus making them 
hollow to impart the floating properties (41). Alternatively, emulsion solvent diffusion 
method can be applied to develop hollow microspheres loaded with drug in their outer 
polymer shell (43). In this case, a solution of drug and polymer, dissolved in an ethanol-
dichloromethane mixture, is poured into an agitated aqueous solution of PVA, with stirring 
to form o/w emulsion droplets (43). The ethanol rapidly partitions into the external aqueous 
phase while the polymer and the drug are induced to precipitate on the outer surface of the 
droplets (43). The remaining dichloromethane enclosed in the droplets suffers evaporation 
Figure 2.11. SEM photographs of (a) outer surface of a hollow microsphere, (b) inner surface of a 
broken half of a hollow microsphere. Adapted from 42. 
Figure 2.12.  Preparation of hollow microspheres by emulsion-solvent dissolution method and 
mechanism of microballoon formation (33, 42). 
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Figure 2.13. Raft forming system mechanism of action. Adapted from 44.  
Gastric Contents 
Raft Forming System 
and diffusion, leaving an air cavity inside the spheres (43). At this point we have hollow 
microspheres developed. 
III. Raft Forming System  
The floating concept can also be applied in the development of various anti-reflux 
formulations, called raft forming systems (31, 44). This name is a result of the capacity of 
these systems to expand and form a foam continuous layer called a raft on the surface of 
gastric contents (Fig. 2.13), blocking the possibility of gastric reflux into the esophagus (31, 
44). When in contact with acidic gastric fluids, the system forms a viscous cohesive gel in situ, 
wherein each portion of the liquid swells forming a continuous layer upon the gastric 
content, containing entrapped CO2 (44). The floating properties of the raft formed are result 
of its low bulk density created by effervescent formation of CO2. When the entire drug 
content is released, at specific desired rate, the system is emptied from the stomach. These 
systems can be formulated as liquid (29) or as tablets (31). The development of raft forming 
tablets (31) may be similar to that found in Fig. 2.4, taking into account all excipient and 
active ingredient’s needs.  
I find it important to mention that Fig. 2.4 represents just a basis of tablet or capsules 
manufacturing process. There might be a need to add further steps or shorten steps, 
accordingly to the formulation characteristics and needs (45). The choice of a method 
requires throughout investigation in many distinct ways.  
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From the distinct types of floating dosage forms described above, only few are possible to 
develop with pharmaceutical conventional equipment. This group includes all effervescent 
gas-generating systems, taking into account the need of a single punch compression machine 
in case of intra gastric bilayer floating tablets, the non-effervescent colloidal gel barrier 
systems and bilayer floating tablets, also requiring a single punch tableting machine, hollow 
microspheres (besides the requirement for very specific development conditions (33, 43)) 
and raft forming systems in the form of tablets. On the other hand, the remaining dosage 
forms may need non-conventional manufacturing equipment or the processes of 
development were not found. This group includes all effervescent volatile liquid or vacuum 
containing systems, and non-effervescent alginate beads because of the need of some 
specialized equipment, namely needle gauges and the equipment used in snap-freezing and 
freeze-drying methods (40).  
 
 
2.2.2. Suitable Drugs and Main Excipients Used In Formulation 
As expected not all drug substances are ideal to be included in floating dosage forms. There 
are some important specific characteristics of drug substances that researchers should 
consider for the development of such systems. Those characteristics are selection criteria 
for potential development of FDDS and are enumerated below (27, 32, 33):   
1. Drugs having incomplete absorption due to a narrow absorptive window in GIT, such 
as riboflavin in a vitamin deficiency and levodopa;  
2. Drugs with site-specific absorption in the stomach or upper part of the small 
intestine, such as chlordiazepoxide and cinnarazine; 
3. Drugs which have local therapeutic action in the stomach, such as antiacids, 
misoprostol and antibiotics against Helicobacter pylori; 
4. Drugs that disturb normal colonic bacteria, such as amoxicillin trihydrate; 
5. Drugs having low stability in the lower parts of GIT, such as metronidazole and 
diazepam. 
Table 2.1 summarizes the drug substances tested FDDS research and development. As we 
can see the majority are developed in the form of tablets and capsules for oral delivery.  
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Table 2.1. Drug substances used in formulation of FDDS according to dosage form (27, 31, 41). 
Besides choosing the most appropriate dosage form for each drug substance, when 
developing novel dosage forms it is crucial to include the most adequate excipients in the 
formulation (46), in order to achieve the best target product profile. This is even more 
important when we are discussing novel dosage forms with such an impact in the 
pharmacokinetic profile of the drug substances (46). The combination of the drug substance 
and the most appropriate and compatible excipients allows the development of dosage 
forms with the desired properties But the process of achieving an adequate formulation is 
complex and takes a long time to perform the necessary research studies (46). In a single 
study several distinct formulations may be evaluated, being studied distinct ratios and 
concentrations of polymers and other excipients.  
Table 2.2 enlists the excipients most widely used in FDDS formulations, according to its 
principle and main function. Low-density inert fatty materials, used in proportions from 5% 
to 75% (34), can decrease the hydrophilic property of the formulation and also increase 
buoyancy (34). Effervescent agents are used in gas generating systems dosage forms, 
accordingly to the classification of FDDS. Release rate accelerants and retardants, in 
proportions from 5% to 60% (34), are used to control the release rate of the drug 
 
FDDS dosage 
form 
Drugs included in floating dosage forms 
Tablets 
Acetaminophen, Acetiylsalicylic acid, Ampicillin, Amoxycillin trihydrate, Atenolol, Captopril, 
Ciprofolxacin, Chlorpheniramine maleate, Cinnariziine, Furosemide, 5-Fluorouracil, Isosorbide 
mononitrate and dinitrate, Diltiazem, Nimodipine, Prednisolone, Quinidine, Riboflavin, Sotalol, 
Varapamil HCl, 
Capsules 
Nicardipine, L-Dopa and benserazide, Chlordiazepoxide HCl, Propanolol HCl, Diazepam, 
Furosemide, Misoprostal, Urodeoxycholic acid 
Films Cinnarizine, Drug Delivery Device 
Microspheres Acetylsalisylic acid, Verapamil, Ibuprofen, Terfenadine, Ketoprofen, Tranilast 
Granules Indomathacin, Diclofenac Sodium, Prednisolone 
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Table 2.2. Examples of polymers and other excipients used in the formulation of FDDS (25, 27, 
28, 32, 34, 41). 
 
 
Type of 
Excipient 
 
Examples 
 
Range of 
concentration 
(%) 
 
Effect on the 
formulation 
Polymers 
HPMC, Eudragit polymers, Calcium alginate, 
Croscarmellose Sodium, Sodium alginate, Propylene foam, 
EC, poly methyl methacrylate, Methocel K4M, 
polyethylene oxide, β-cyclodextrin, CMC, PEG, 
polycarbonate, PVA, HPC-L, HPC-H, HPC-M, CP 934P, 
Metolose S.M. 100, PVP,  polyox,  acrylic polymer, 
xanthan gum, guar gum, carbopol, polyvinyl acetate, agar 
- - 
Inert Fatty 
Materials 
Beeswax, fatty acids, long chain fatty alcohols, Gelicures 
39/01 and 43/01 
- 
Decrease 
hydrophilic 
properties and 
enhance the 
buoyant 
capacities 
Effervescent 
Agents 
Sodium bicarbonate, citric acid, tartaric acid, Di-Sodium 
Glycine Carbonate (Di-SGC), citroglycine (CG) 
- 
Gas generation 
in effervescent 
FDDS 
Release Rate 
Accelerants 
Lactose, mannitol 5-60 
Increase the 
release rate of 
drug substance 
Release Rate 
Retardants 
Dicalcium Phosphate, talc, magnesium stearate 5-60 
Decrease the 
release rate of 
drug substance 
Buoyancy 
increasing 
agents 
EC Up to 80 
Enhance the 
buoyant 
capacities 
Low Density 
Materials 
Accurel MP 1000 7 – 75 
Enhance the 
buoyant 
capacities 
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substances, as the name suggests. Buoyancy increasing agents, used up to 80% (34), are used 
to enhance the buoyant capacities of the dosage form, as much as low density materials (34). 
It is crucial that companies have conditions to store excipients accordingly to each ones 
specifications in order to avoid stability problems.   
Recently, Eberle et al (48) described a pharmaceutical excipient showing great and improved 
buoyancy characteristics suitable for the preparation of floating tablets and for the 
development of future innovative FDDS: functionalized calcium carbonate (FCC). This 
excipient is highly porous and has an inherent low apparent density, approximately 0.6 g.cm-3 
that enables a mechanism of buoyancy of tablets with no lag time, showing almost instant 
flotation (48). Additionally, it has a higher specific surface, approximately 70 m2, which allows 
sufficient hardness for further processing. FDDS based on FCC appear to be promising (48). 
 
 
2.2.4. Factors Affecting the Floating Process  
Making a reliable and predictable gastroretentive formulation, in particular FDDS, is a very 
difficult process since its success depends on formulation and idiosyncratic factors that 
influence the gastric retention time of the oral dosage form (32).  
The formulation factors, as the name suggests, are related to composition of the dosage 
form, such as the polymers and excipients selected, the characteristics of powders and 
dosage forms obtained, and others (32). Below it is a description of the formulation factors 
mentioned in literature.  
1. Density. The buoyant properties of floating dosage forms are dependent on the 
density of the dosage form. It is required a density lower than gastric contents (<1 
g.cm-3), to exhibit floating properties in order to increase gastric residence time (28, 
44).  
2. Size. The size of the dosage form is very important to increase gastric retention of 
floating dosage forms. It is mandatory to have a size small enough to pass through the 
esophagus and larger enough not to be emptied from the stomach into the intestine 
(28, 44). Besides that, the size is reported to be more important in non-floating 
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dosage forms, once floating dosage forms adopt a buoyant behavior when in contact 
with gastric fluids and this is registered regardless their sizes (32).  
3. Shape. Studies in beagle dogs reported that tetrahedron ring shaped dosage forms 
(over 6 distinct shapes) exhibit higher gastric retention. A further study was 
conducted in human volunteers in order to confirm the results. It was demonstrated 
an 100% gastric retention of tetrahedron dosage forms at 24 hours in beagles, but 
only one of the human volunteers showed 12 hours retention of the dosage form in 
the stomach (48). Further studies should be carried out to determine if effectively 
tetrahedron shaped dosage forms are the most suitable for larger gastric retention 
times. 
4. Viscosity grade of polymer. Viscosity of polymers and interactions (between 
excipients and water) are determinant for the drug release and floating properties of 
these formulations (49). Concerning floating properties, it is reported that low 
viscosity polymers are more beneficial than high viscosity polymers, and that the drug 
release rate increases when the polymer viscosity decreases (49).  
5. Single or multiple unit of dosage form. As referred previously in this 
monograph, a multiple unit dosage form shows several advantages over single unit 
dosage forms. This is determinant for the efficiency of dosage forms because multiple 
unit formulations allow the co-administration of units with distinct release profiles or 
drug substances, they have a more predictable behavior and show a shorter margin 
of failure when compared to single unit formulations.  
Otherwise, idiosyncratic factors are related to what concerns human physiology and factors 
influencing the performance of drug administration and processing (32). At this point it is 
crucial to understand that the gastrointestinal movements play an important role in the 
efficacy of each drug delivery device, as much as pharmacokinetic and pharmacodynamic 
properties (46). Below it is a description of the most important idiosyncratic factors 
described in literature: 
1. Gender. Women have slower values of ambulatory gastric emptying than men when 
comparing people of both genders with the same age and also the gastric resident 
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time of dosage forms in higher in females, regardless of weight, height or body 
surface area (50).  
2. Age. The aging process is associated with alterations in body functions and 
metabolism. It is reported that elderly, especially those over 70, have significant 
prolonged gastric residence time than younger individuals (50). This result was 
obtained with healthy elderly individuals in a way that the effects of aging are 
separated from disease state (50).  
3. Posture. Mojaverian et al (50) reported no significant difference in the GRT of 
individuals in ambulatory upright and supine positions. Otherwise, it is reported that 
floating dosage forms have more probability to suffer undesired and faster emptying 
from the stomach in supine position, while in the ambulatory upright position floating 
dosage forms remain buoyant above gastric contents irrespective of its size and thus 
showing prolonged gastric residence time (30).  
4. Disease state. Literature reports some disease conditions that may affect drug 
action and delivery including floating dosage forms, namely Crohn’s disease, an 
inflammatory bowel disease that can affect any part of the GIT, diabetes, gastric ulcer 
and others (31, 44).  
5. Concomitant intake of drugs. Concomitant administration of drugs or 
pharmaceutical excipients, which modify motility of GIT and gastric emptying rate, 
may affect the performance of FDDS (32). These type of drugs include prokinetic 
agents (e.g., metoclopramide and cisapride), anti cholinergics (e.g., atropine or 
propantheline) and opiates (e.g., codeine) (32). 
6. Meal Composition. The caloric density of a meal plays an important role in 
controlling gastric emptying rate in humans and it is reported that this relation is 
independent of the nature of calories (51). As long as the caloric density is the same, 
it does not make difference whether the meal has high content of proteins, fat or 
carbohydrates (51). The nature of meals also has implications in gastric emptying 
rate. The motility pattern of the stomach can be changed to a fed state by feeding of 
indigestible polymers or fatty acid salts, thus decreasing the gastric emptying rate and 
prolonging drug release and enhancing drugs oral bioavailability (31, 34). 
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7. Feeding Regimen. The presence or absence of food (fed and fast state, 
respectively) in the stomach and the frequency of feed are factors that influence 
gastric residence time of the dosage forms. As referred on the Introduction (Section 
1.3.3. and Fig. 1.5), in fasting conditions the gastric motility is characterized by strong 
motor activity that occurs every 2 to 3 hours, and it sweeps the undigested material 
from the stomach. If the time of administration of a dosage form coincides of that of 
MMC, the gastric retention time of the device is expected to be very short (34). 
Otherwise, in the presence of food, as MMC is delayed, gastric residence time of 
dosage forms is considerably longer, and it increases drug absorption (30, 34). 
As formulation factors are relatively easy to adapt and control, idiosyncratic factors are the 
most problematic since they are exposed to intra and intervariability and most of the times 
are difficult to predict. Finding the better formulation that allows overcoming the difficulties 
imposed by both factors can be an expensive and long process, as investigation may go by 
several years. Idiosyncratic and formulation factors may not be studied independently, but 
interdependently in order to achieve the best and more efficient formulation.  
 
2.2.4. Advantages and Limitations 
There is a wide range of advantages sustaining the development of floating delivery systems 
over conventional dosage forms. Although some of those advantages are exclusive of FDDS, 
others are shared with other drug delivery systems. The advantages are: 
- In case of vigorous intestinal movement and diarrhea, FDDS are advantageous 
because they remain buoyant at the surface of gastric contents, avoiding undesired 
emptying (30, 32, 34).  
- FDDS are advantageous for drugs acting locally in the stomach, such as antacids, or in 
the proximal part of the small intestine, and for drugs that act in gastrointestinal 
diseases such as esophageal reflux, and for drugs absorbed through the stomach, such 
as ferrous salts (30, 32, 34). In those cases, there is an improvement of drug 
absorption due to a prolonged gastric retention time and prolonged time of the 
dosage form in the absorption site (34). 
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- May increase patient compliance by decreasing dosing frequency (30). 
- Prolonged release floating dosage forms, especially tablets and capsules, will allow 
dissolution of the drug substance in the gastric fluids (32). Consequently they will be 
available for absorption in the small intestine after emptying of gastric contents. This 
implies that the drug remains in solution for prolonged time even at alkaline pH of 
the intestine (30, 32). 
- The fluctuations in plasma drug concentrations are minimized as much as it is possible 
to prevent concentration-dependent adverse effects that are associated with peak 
plasma concentrations of drugs (32).  
- Multiple unit systems have advantages over single unit systems: there is a smaller risk 
of dose dumping and can ensure an uniform drug release (33). 
 
Nonetheless, FDDS have also some limitations that must be taken into account since they 
may affect the performance and viability of the system. The limitations are: 
- These dosage forms are not appropriate for drugs that irritate the gastric mucosa 
because of their prolonged gastric residence time (34). 
- Gastric emptying of FDDS is influenced by factors such as gastric motility, pH and 
presence of food, which vary significantly from one person to another and 
compromises a precise prediction of the buoyant behavior (34).  
- Floating formulations require a sufficient amount of fluids in the stomach to achieve a 
buoyant state and work efficiently (21, 32, 34) and also require the presence of food 
to delay their gastric emptying, in order to increase bioavailability of the drug 
substance (34). 
- Drug substances showing low stability and solubility in acidic gastric fluids or in the 
GIT are not appropriate to be incorporated in floating systems (31, 32, 34). 
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- Drugs that undergo extensive first-pass metabolism are not desirable candidates for 
the preparation of buoyant dosage forms, because the slow gastric emptying may 
result in low systemic bioavailability of the drug substances (31, 34). 
- It is not feasible to administer a FDDS before going to bed because, as said 
previously, in supine position there is a higher risk of undesired and faster emptying 
of the dosage form from the stomach and consequently a higher risk of loss of its 
efficacy (29, 34). 
 
2.2.5. In Vitro and In Vivo Evaluation 
When developing a floating gastroretentive drug delivery system it is important to evaluate 
the performance of the dosage forms obtained, being some parameters determined in vitro 
while others are evaluated in vivo (28, 31). Although both are relevant, good in vitro results 
do not necessarily imply good in vivo performances because it is not possible to have good 
correlations in vitro / in vivo. Only in vivo studies provide definite proof of enhanced gastric 
residence times obtained with buoyant formulations (28, 30, 32). Below there is a 
description of these evaluations techniques.  
2.2.5.1. In Vitro Studies 
FDDS should be characterized in vitro for parameters such as specific gravity, porosity, 
buoyancy, floating lag time and others. For example in tablet formulations pre-compression 
and post-compression parameters can give an idea of their efficacy (34). In summary, FDDS 
should be evaluated for the following parameters in vitro:  
1. Floating lag time and floating time measurements are usually carried out in 
simulated gastric fluid containing 900mL of 0.1 M HCl (pH 1.2) as a testing medium 
maintained at 37 ºC in USP dissolution paddle apparatus II (31, 32, 34). The floating 
time represents the total time that the dosage form remains buoyant in the same 
medium (31).  
2. Drug release or dissolution studies are also performed in USP dissolution paddle 
apparatus II in simulated gastric fluids maintained at 37 ºC (30, 32). While doing these 
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tests, samples are withdrawn periodically from the dissolution medium and replaced. 
Then the samples are analyzed for their drug content after an appropriate dilution, 
giving information about the quantity of drug that was released along the test (30, 
32). These studies are part of the necessary studies to determine pharmacokinetic 
process and are important to understand the process of degradation or erosion rate 
of the formulation in the stomach (52).  
3. Swelling index is measured by studying weight gain or water uptake after 
immersion of the dosage form in simulated gastric fluid at 37 ºC and analysis in terms 
its diameter and/or thickness as a function of time (32, 34). The floating tablets are 
removed from the beaker at regular time intervals of 1 hour for 24 hours, and then 
reweighed. The water uptake (WU) is measured in terms of percent weight gain, as 
given by the Equation 2.1., in which Wo is the initial weight of the dosage form and 
Wt its weight at time t.  
WU = [(Wt – Wo)/Wo] x 100                        Equation 2.1 
 
But USP dissolution paddle apparatus II does not mimic gastric environment in vivo and so, 
good in vitro-in vivo correlation (IVIVC) is dubious. With this apparatus the studies are carried 
out as a function of time, but it would be advantageous to evaluate those parameters as a 
function of gastric emptying (52), making it possible to reduce individual variability. Highly 
acidic environments used as dissolution medium favor gas generation and push the floating 
process. But in the stomach even neutral pH values may be observed as a result of poor 
mixing and the impact of food, making a pH-independent (in a pH range 1 – 7.4) floating 
performance desired (53).  
Alternatively Gohel et al (54) proposed a more relevant in vitro dissolution method to 
evaluate tablet dosage forms of FDDS, which mimics gastric conditions more efficiently. A 
100 mL glass beaker was modified by adding a side arm at the bottom of the beaker so that 
it can hold 70 mL of dissolution medium similar to the one used in USP paddle apparatus II. 
A burette was mounted above the beaker to deliver the dissolution medium at a flow rate of 
2 mL/min to mimic gastric acid secretion rate. This test may show good IVIVC since an 
attempt is made to mimic the in vivo conditions such as gastric volume, gastric emptying and 
gastric acid secretion rate. 
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2.2.5.2. In Vivo Studies 
In vivo studies are performed in animals in a first approach or in patients. The aim is to 
evaluate the performance of buoyant dosage forms in the stomach. As said previously, this 
type of studies provide definite proof of prolonged gastric residence time of FDDS. Some 
techniques for the in vivo evaluation are enumerated below: 
1. X-ray is a very popular technique for the evaluation of floating dosage forms. By 
inclusion of a radio-opaque material into the dosage form it is possible to have access 
to the location of the dosage form in the GIT by X-ray analysis. This allows a 
correlation between gastric emptying time and the passage of the dosage form in the 
GIT (30). Just before the administration of the dosage form it is made a radiograph in 
order to ensure the absence of radio-opaque material in the stomach. After that, the 
dosage form is administered and a radiograph image is taken every 30 minutes with 
the equipment at a constant distance from the subject so that the movement of the 
dosage form can be easily noticed (32). This method has some limitations regarding 
the levels of exposure to x-rays and the requirement of high quantity of radiologic 
images (29, 32), but it has the advantage of being simpler and cheaper than gamma-
scintigraphy.   
2. Gamma-scintigraphy is also a very popular technique for the in vivo evaluation of 
buoyant dosage forms. By inclusion of a properly short lived γ-emitting radioisotope 
in the formulation, it becomes possible to perform indirect external observation of 
the dosage form location in the GIT using a γ-camera or scintiscanner (32). The 
drawbacks associated with this method are the associated ionizing radiation for the 
patient, the limited topographic information, low resolution inherent to the 
technique and the expensive preparation of radiopharmaceuticals (31).  
3. Gastroscopy is an invasive and aggressive method because it comprises a peroral 
endoscopy with a fibereoptic and video systems (28). This method may be used to 
inspect visually the effect of prolonged stay in stomach milieu on buoyant dosage 
forms. This technique also allows the removal of the dosage form from the stomach 
for more detailed evaluation and information.  
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4. Ultrasonography is not routinely used for the evaluation of FDDS. This method 
allows imaging of some abdominal organs due to their acoustic impedances across 
interfaces that are reflected by ultrasonic waves (28). But floating formulations do 
not commonly have sharp acoustic mismatches across their interface with the 
physiological milieu. Nonetheless, ultrasonography characterization includes 
assessment of intragastric location of hydrogels, solvent penetration into the gel and 
interactions between gastric wall and FDDS during peristalsis (28). 
The necessity to do, at least, some of those evaluations, may represent a drawback to 
companies that may want to develop floating dosage forms. They must be aware of the 
necessity to evaluate formulation parameters and must be able to perform them or to 
establish agreements with other companies that may do these tests for them.  
Anyway, the problem mentioned above regarding the dissolution apparatus used may be 
further studied, because dissolution methods do not provide accurate in vitro conditions for 
gastroretentive formulations. There is still the need to develop an optimum in vitro floating 
time testing method for a floating dosage form that can efficiently evaluate the effect of fed 
and fasted states in gastric region on the floating capabilities of the developed product (46). 
 
 
2.2.6. Market and Regulatory Considerations 
Literature describes an extensive number of studies and research papers on FDDS 
encompassing the different types of floating systems (24, 25, 29, 33, 46), but getting them 
further into the market is a hard task represented by the conflict between investigation and 
industrial implementation of all gastroretentive delivery systems (46): only few technologies 
have been commercialized. The success of a formulation is dependent on preformulation 
studies, optimization studies, and scale up and process validation of developed manufacturing 
process. Many investigations are limited to the laboratory instead of reaching the market 
because it is much easier to manufacture a commercial scale batch in the laboratory than a 
large-scale batch in industry (46). Also due to high intra and intervariability among 
individuals, studies of bioequivalence and bioavailability of GRDDS are more demanding and 
this represents a considerable obstacle to formulations aiming to achieve the market. 
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Table 2.3. Gastroretentive systems available in the market (27, 28, 31, 41, 44, 46, 55). 
 
Name 
 
Drug Substance 
 
Type of Dosage Form 
 
Company Name 
Almagate 
Flot-Coat ® 
Aluminum and  
Magnesium antacid 
Floating dosage form 
Laboratorios Almirall SA 
(Spain) 
Baclofen GRS Baclofen 
Coated multi-layer floating and swelling 
system 
Sun Pharma (India) 
Cifran OD ® Ciprofloxacine Effervescent floating tablet Ranbaxy (India) 
Cipro XR 
Ciprofloxacin HCl and 
betaine 
Erodible matrix-based system Bayer (USA) 
Conviron Ferrous Sulphate Colloidal gel forming FDDS Ranbaxy (India) 
Coreg CR Carvedilol Gastroretention with osmotic system GlaxoSmithKline (India) 
Cytotec Misoprostol Bilayer floating capsule Pharmacia, Ltd (USA) 
Inon Ace 
Tablets 
Siméthicone Foam-based floating system Sato Pharma (Japan) 
Liquid 
Gaviscon® 
Aluminum Hydroxide and 
Magnesium Carbonate 
Effervescent floating liquid alginate 
preparation 
GlaxoSmithKline (India) 
Madopar HBS 
® 
Levodopa and benserazide Floating controlled release capsule Roche Products (USA) 
Oflin OD ® Ofloxacin Effervescent floating tablet Ranbaxy (India) 
Prazopress XL Prazosin HCl 
Effervescent and swelling-based floated 
system 
Sun Pharma (India) 
Riomet OD Metmorfin HCl Effervescent floating system Ranbaxy (India) 
Topalkan ® 
Aluminum and Magnesium 
Alginate 
Floating liquid alginate preparation 
Pierre Fabre Drug 
(France) 
Valrelease ® Diazepam Floating controlled release capsule 
Hoffmann – La Roche 
(USA) 
Xifaxan Rifaximin Bioadhesive tablets Lupin (India) 
Zanocin OD Ofloxacin Effervescent floating system Ranbaxy (India) 
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Table 2.3 gives details about marketed products of gastroretentive dosage forms including 
various types of floating systems. The market has more floating systems than any other form 
of GRDDS, and it was not found any reference to the existence of high density systems on 
the market (46). Among those, solid capsules and tablets are the most common final dosage 
forms, having more products on the market than liquid preparations for example. But it does 
not count with many products available. India is the country where these dosage forms are 
widely disseminated, being Ranbaxy the leader in terms of marketed products. Nonetheless 
of the number of floating dosage forms is low, it is growing as technological and 
pharmaceutical knowledge increases.  
 
 
2.3. Conclusion 
Gastroretentive floating drug delivery systems have the capacity to prolong gastric residence 
time without affecting the motility of GIT. The dosage form is retained in the stomach, 
allowing the drug to reach its absorption site in solution and hence be ready for absorption, 
and increasing oral drug bioavailability.  
Besides being a promising drug delivery system that allows overcoming some limitations of 
conventional dosage forms, there is a problem of accuracy in dissolution tests. And this 
represents difficulties for those companies that want to innovate and develop FDDS, because 
some FDDS can be manufactured using conventional equipment but conventional equipment 
normally used for the in vitro characterization of the dosage forms does not provide a 
satisfactory IVIVC. This means that the most commonly used dissolution apparatus is not the 
most appropriate. For further advancing in the development of these novel dosage forms it is 
very important to develop alternative dissolution apparatus that may evaluate the floating 
parameters as a function of gastric emptying instead of time, so that better IVIVC may be 
achieved. As a consequence, nowadays in vivo studies are still very important to establish the 
optimum dosage form for a specific drug. It is also a challenge to choose either a drug 
substance or the excipients, in order to achieve the target product profile. Many other 
factors are important when aiming to get a floating or other gastroretentive formulation 
commercialized. The market of gastroretentivity is still small, which may represent an 
opportunity, as the research in this area is already substantial. Besides the growth observed 
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in investigation and in market of GRDDS, these dosage forms are not yet described in 
United States Pharmacopoeia (USP) or in European Pharmacopoeia (Eur. Ph.). 
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3.1. Medicated Chewing Gums  
Chewing gums are widely consumed by society, but with the development of science and 
technology it is now considered a promising and convenient drug delivery system (56). It was 
in 1869 that the first patent for the production of chewing gum was filled (57), and the first 
medicated chewing gum Aspergum with the DS acetylsalicylic acid was launched almost 60 
years later, in 1928 (56). Nevertheless, it was only in late 70s that chewing gums gained 
acceptance as a reliable drug delivery system, when nicotine chewing gum became available 
(58). Only in 1991 MCG were included as a pharmaceutical dosage form in the Eur. Ph. and 
the guidelines for this pharmaceutical dosage forms were issued by the Committee for 
Medicinal Products for Human Use (56, 58). In there, they are described as “solid, single 
dose preparations with a base consisting mainly of gum that is intended to be chewed but 
not swallowed, providing a slow, steady release of the active ingredients contained” (59). 
MCG are meant to act locally, in both prevention and cure of oral diseases, or systemically 
when there is a direct absorption through the buccal mucosa (56, 58). Due to the high 
vascularization of buccal mucosa (see Introduction Section 1.3.1.), the drug substance can be 
directly absorbed into the systemic circulation, avoiding first pass metabolism and enabling a 
faster onset of action and higher oral bioavailability (60). Besides this route of absorption, a 
portion of the drug substance may reach the stomach dissolved in saliva and be available for 
gastrointestinal absorption (60). The active drug substance is released from the dosage form 
as a result of the mechanical and chemical masticatory act (58), so it is required a continuous 
chewing process, saliva and a minimum chewing time (56). 
This dosage form has been formulated and commercialized for a wide range of active 
substances (56, 58), taking advantage of its characteristics that are able to enhance patient 
compliance, including the attraction it represents to children over other formulations (58). 
Many of them are used for systemic purposes such as pain killers, vitamins, alertness 
enhancers, motion sickness removal and smoking cessation gums (56), while others are 
commercialized for local purposes, like plaque acid neutralization, fresh breath and bacterial 
infections (56). MCG are developed according to superior quality standards and Good 
Manufacturing Practices (GMP) (58), which are imperative parameters to be taking into 
account, making it a reliable drug delivery system. This drug delivery system is subject to 
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quality control parameters evaluation in order to guarantee quality and security of the MCG 
before reaching the market (58). In vivo testing may also be required.  
 
 
3.1.1. Manufacturing Processes 
Medicated chewing gums have the possibility to be manufactured by three distinct methods: 
A. Conventional/Traditional Method (Melting) 
B. Cooling, Grinding and Tableting Method 
C. Direct Compression Method. 
 
The Conventional/Traditional Method (Melting) consists of five process steps, as briefly 
described in Fig. 3.1 (56, 58, 60, 61):  
1. The components of gum base are softened or melted in a Kettle mixer; 
2. The drug substance and other excipients are added at a determined time; 
3. The gum is sent through a series of rollers that transform it into a thin and wide 
ribbon. During this step a light coating of finely powdered sugar (or sugar substitutes) 
is added in order to avoid sticking phenomena and to enhance the flavor; 
4. Then it is cooled for up to 48h in controlled conditions; 
5. Finally, the gum is cut in the desired size and cooled under controlled temperature 
and humidity.  
There are some limitations associated with this process, namely: 
- Requirements for elevated temperature during melting, make the manufacture of 
thermoliable drugs a challenge; 
- Difficulty to control the accuracy and uniformity of drug dose if the gum mass is 
highly viscous; 
- Lack of precise form, shape or weight of dosage form; 
- Difficulties to formulate chewing gum as tablets due to high moisture content (2-8%). 
The composition may adhere to the grinding apparatus and to punches, hampering 
the compression process.   
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Cooling, Grinding and Tableting Method (Thermoliable) arrised as an attempt to overcome 
the limitations of the Conventional Method by lowering the moisture content (56, 58, 60, 
61). This method consists of three process steps, as are briefly described in Fig. 3.2: 
1. Cooling. The gum base is cooled to a temperature at which the composition is 
sufficiently brittle, even for the further step, by addition of a coolant. Such 
temperature is determined by the gum base composition, and it generally around -
15ºC. It is desired for the coolant not to be absorbed during the process, not to 
interact adversely with the processing apparatus and not to leave behind undesirable 
or potentially hazardous residues. The use of solid silicon dioxide is preferred. 
2. Grinding. The refrigerated gum composition is placed in a mill grinder and is ground 
to obtain minute fragments of finely pieces. Additionally, anti-caking agents such as 
Figure 3.1. Conventional Method for the manufacturing of MCG (56, 58, 60, 61). 
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precipitated silicon dioxide and grinding agents can be added, in order to prevent 
agglomeration and to prevent the gum composition from sticking to the grinding 
apparatus, respectively. 
3. Tableting. The coolant is removed from the powder, and the powder is mixed with 
other excipients (e.g., binders, sweeteners and others) in a suitable blender such as 
high shear mixing. The granules obtained may be mixed with antiadherents like talc. 
Finally, the powder is compressed in a conventional compression machine.  
This method has also some limitations such as the need of specific equipment (other than 
conventional tableting equipment) and the challenge of monitoring humidity during the 
 
 
 
Figure 3.2. Cooling, Grinding and Tableting Method for the manufacturing of MCG (56, 58, 60, 
61). 
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manufacturing process. Besides those limitations, this method is more convenient than the 
conventional method (56, 58, 60, 61). 
 
The Direct Compression Method allows an easier and faster manufacturing process of the 
chewing gum if directly compressible gum bases are available, and can overcome the 
limitations of conventional manufacturing methods (56, 58, 60, 61). Pharmagum, a mixture of 
polyols and sugars with a chewing gum base, is one such compactable system developed by 
SPI Pharma that was available as a directly compressible powder, free flowing powder. This 
mixture could be compacted into a gum tablet using conventional tablet press thus enabling 
rapid and low cost development of a medicated chewing gum delivery system (56, 58, 60, 
61). Pharmagum, which was manufactured under GMP conditions and was considered 
“Generally recognized as safe” (GRAS), was available in three forms namely S, M and C, that 
differ on their composition. But for unknown reasons SPI Pharma stopped commercializing 
this excipient. Other example is Health in Gum developed by Cafosa that is a directly 
compressible powder gum containing a mixture of gum base and polyols, which only requires 
addition of an active ingredient prior to compression (62). Health in Gum has been created to 
turn the manufacturing process of chewing gums quick and cost-effective (62). It performs 
 
Figure 3.3. Schematic diagram of MCG manufacturing process by Direct Compression Method, 
based on the use of Health in Gum as a directly compressible powder (56, 58, 60, 61).  
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excellently using standard tableting equipment, with no need for chewing gum specific 
equipment, and works at room temperature, allowing the use of thermos-sensitive DSs (62). 
Fig. 3.3 describes the manufacturing steps of Medicated Chewing Gum using Health in Gum as 
a directly compressible powder to which the DS is added (63). With this method a 
pharmaceutical company that possesses standard direct compression technology is able to 
develop MCG. 
 
 
3.1.2.  Suitable Drugs and Main Excipients Used In Formulation  
Medicated Chewing Gum is a solid, single dose innovative dosage form composed of a 
masticatory water insoluble gum base with at least one active drug substance (56). The gum 
base generally comprises a water insoluble chewable gum portion and a water soluble bulk 
portion (60, 64), although a wide variety of excipients can be used as listed in Table 3.1. The 
water insoluble gum base generally comprises elastomers, plasticizers and fillers or 
texturizers (60). Elastomers are used in a percentage of 40 – 70 % by weight of the total 
gum base (60), in order to provide elasticity, gummy texture and cohesion to the chewing 
gum (58). Plasticizers are used in a percentage of 3 – 20 % by weight of the gum base (60), in 
order to regulate the cohesive properties of the gum base (58). Fillers or texturizers, which 
are used in a percentage of 2 – 60 % of the gum base (60), provide an appropriate texture, 
improve chewability and provide reasonable size of the gum lump with low dose drugs (58). 
The water soluble bulk portion of the gum base generally comprises softeners, emulsifiers, 
sweeteners, flavoring agents and others (60) which are shown in Table 3.1. Resins contribute 
to achieve a balance between the properties of elasticity and plasticity and have two 
functions: being a binding agent between elastomers and fillers, and being a mastication 
substance (58). Emulsifiers and fats are used to soften the mixture and are responsible for 
giving the required chewing consistency and pleasant mouth feel (58), function that it is 
common with softeners. Emulsifiers also have the function of promoting the uptake of saliva 
into the chewing gum during the mastication process. Antioxidants are used to prevent the 
oxidation of the gum base and flavors (58). Sweeteners, which are used in a proportion of 50 
– 65 % of gum base composition (60), are of two types (aqueous and bulk sweeteners) and 
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Type of 
excipient 
% of 
usage  
Examples 
Elastomers 40 – 70 
Natural: latex, jelutong, Leche Caspi, Perillo, Chicle 
Synthetic: polyisobutylene, butyl rubber 
Plasticizers 3 – 20 
Natural: glycerol esters of partially hydrogenated rosin, of polymerized 
esters, and of partially dimerized rosin, pentaerytthritol esters of resin 
Synthetic: terpen resins derived from α-pinene and d-limonene 
Fillers or 
texturizers 
2 – 60 
Magnesium and calcium carbonate, ground limestone, alumina, talc, 
titanium oxide & mono/di/tri calcium phosphate 
Resins -  
Natural: glycerol esters from pine resins 
Synthetic: polyvinyl acetate 
Emulsifiers  
and fats 
-  Monoglycerides, diglycerides, partly hardened vegetable and animal fat 
Softeners -  
Glycerin, lecithin, tallow, hydrogenated tallow, mono/di/tri-glycerides, 
fatty acids like stearic acid, palmitic acid, oleic acid and linoleic acid 
Antioxidants -  Ascorbic acid, tocoferol, butylhydroxytoluene 
Sweeteners 50 – 60 
Aqueous: sorbitol, hydrogenated starch hydrosylates, corn syrups 
Bulk 
Sugar components: saccharides (sucrose, dextrose, 
maltose, dextrin, fructose, galactose, corn syrup) 
Sugarless components: sugar alcohols (sorbitol, 
mannitol, xylitol, hydrogenated starch 
hydrosolated) 
Flavoring 
Agent 
-  
Citrus oil, fruit essences, peppermint oil, spearmint oil 
mint oil, clove oil, oil of wintergreen 
Anti-Caking 
Agent 
-  Precipitated silicon dioxide, solid carbon dioxide 
Grinding 
Agent 
2 – 8 Alkaline metal phosphate, malt dextrin 
Table 3.1. Main excipients used in formulation of gum base for MCG (56, 58, 60, 64). 
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can be used as softeners to blend the ingredients and retain moisture. In order to provide 
longer lasting sweetness and flavor perception, high intensity artificial sweeteners such as  
sucralose, aspartame, saccharin and others, can be added (58). Flavoring agents are used to 
improve the flavor in chewing gums and include a variety of essential oils as well as artificial 
flavoring agents (58). The anti-caking agents may be added to the mixture prior to grinding in 
order to help preventing agglomeration of the subsequently ground chewing gum particles 
(58). Grinding agents are used to prevent the gum from sticking to the grinding apparatus, 
but should be applied rationally due to their tendency to remain in the composition and final 
chewing gum tablet, which may be problematic from a safety point of view (58). They also 
have a limited practical use due to the incompatibility of their high alkaline characteristics 
with acidic ionisable therapeutic agents (58). Bulking agents such as polydextrose, 
oligofructose and guargum hydrolysate may also be used if low calorie gum is desired (60). It 
is also important to understand that the formulation has a very low content of water (58, 
60) due to the necessity of maintaining the integrity of the dosage form once in contact with 
saliva in the oral cavity, because it is intended to be chewed and discarded after drug release. 
The gum base composition is determinant for the basic characteristics of the product, such 
as texture, elasticity and mouth feel, and also for release profile of active ingredients and of 
sweeteners and flavors (60). Therefore, the release profile of sweeteners and flavors is 
usually designed to follow the release profile of the drug substance (64). 
The gum core may be coated (60). The coating can be applied as a film of polymers, waxes, 
sweeteners, flavors and color or as a thick layer of sugar or sugar alcohol.  
The active drug substance may be included in gum core, in the coating layer or in both, and 
the final percentage of drug load may vary between 0.5 – 30 % (60). It is crucial to 
understand the effects of the nature of DS and its physicochemical characteristics in the 
formulation, in order to develop an appropriate dosage form. First it is important to 
understand that the active DS must not have a particle size higher than 100 µm, so that the 
unpleasant gritty feeling during chewing is avoided and the patient compliance is not affected 
(56, 58). Chemical characteristics of the drug substance are also important when aiming to 
develop MCG, namely its lipophilicity and hydrophilicity (58). While hydrophilic active 
substances are rapidly and completely released from gum core, lipophilic drug substances 
adhere and are dissolved in the gum base, being slowly and incompletely released (60, 65). 
Taking this into account, there is a necessity for optimization of the formulation accordingly 
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to the drug substance’s nature. The release rate may be decreased in case of hydrophilic 
substances, for example, by its encapsulation or by increasing the amount of gum base (65), 
and may be increased in case of lipophilic drugs, for example, by its coating/encapsulation or 
by the addition of buffering or solubilizing agents (60, 65).  
Any aspect of the formulation may be controlled and considered together and not 
independently to achieve an optimal formulation with acceptable organoleptic and 
technological properties (66) and to get it successfully into the pharmaceutical market. 
 
 
3.1.3.  Factors Affecting Drug Release 
 
There is a wide range of factors affecting the drug released from Medicated Chewing Gums 
(56, 58, 60, 66), and those factors can be divided in three main groups: 
   
1. Physicochemical properties of drug substance. As said previously in this 
monograph, aqueous solubility of the active drug substance plays an important role in 
the success of the formulation, since saliva is mainly composed of water and the 
volume of saliva is small (60). So considering the same chewing conditions, 
hydrophilic drugs will be released quickly and at a higher amount than lipophilic drugs 
(60). Besides the physicochemical properties of drug substance, also its amount in the 
formulation is an important factor. As a consequence, the components of the 
chewing gum may be selected accordingly to the nature and requirements of the drug 
substance.  
2. Properties of the gum base (formulation factor). Composition and amount of 
gum base affect the release rate of drug substance (56, 60). For example, if lipophilic 
portion of gum base is increased, it implies a decrease in release rate of hydrophilic 
drugs (56, 60). Therefore, the formulation may be adjusted to achieve the target 
product profile for each specific drug substance. 
3. Chew-related factors. These factors include contact time, chewing frequency and 
intensity, membrane factors and environmental factors, which may vary from 
individual to individual.  
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3.1. Contact time. The contact time of the dosage form in the oral cavity influences 
the local or systemic effect of drug substance (64). Literature reports a chewing 
time of around 30 minutes to be appropriate (61). 
3.2. Chewing frequency and intensity. These variables play an important role in the 
success of drug release from MCG. In vitro studies are carried out accordingly to 
Eur. Ph. specification of 60 chews per minute for proper release of active ingredient 
(67). 
3.3. Membrane factors. These factors are related to the characteristics of buccal 
mucosa and the processes related to the drug absorption (60). Regional differences 
may affect drug release and absorption to systemic circulation, namely permeability 
and thickness of buccal mucosa and its keratinization and composition, as referred 
on the Introduction part 1.3.1. Other factors that also influence drug release and 
absorption are blood supply, blood/lymph drainage, cell renewal rate and enzyme 
content of saliva.  
3.4. Environmental factors. These factors are related to saliva, its properties and 
flow rate (60). An increase in the flow rate will lead to the secretion of watery 
saliva. Salivary pH (6.5 – 7.5) depends on the salivary flow rate and location in the 
oral cavity, and may influence the passive diffusion of the unionized drug (60). 
In order to achieve the best and more efficient formulation, each factor should be evaluated 
having in mind the dependency on the others.  
 
 
3.1.4.  Advantages and Limitations 
There is a wide range of advantages sustaining the development of Medicated Chewing 
Gums over conventional dosage forms. This novel pharmaceutical dosage form provides 
competitive advantages over conventional drug delivery systems, while other advantages are 
shared with different delivery systems. These advantages are: 
- Chewing gums do not require water to be administered once they are meant to be 
chewed not swallowed, and so the administration can occur anywhere without 
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water. So it represents an advantage for patients having difficulty in swallowing and 
for children (68); 
- Not being swallowed, the chewing gum barely reaches the stomach, thus decreasing 
the risk of side effects due to the excipients and/or active ingredients. The fraction 
that reaches the stomach is conveyed by saliva, thus there is no direct contact with 
high concentration of drug and it is presented in a readily bioavailable form (61). 
Because of this there is a lower risk of intolerance of gastric mucosa to the 
components of the MCG (60);  
- Once the patient starts chewing, the active substance is released from the gum. High 
plasma peak concentrations of the drug are avoided by promoting a controlled drug 
release, thus resulting in fewer side effects (58); 
- Depending on the active ingredient, some absorption takes place in the buccal 
mucosa, allowing a systemic delivery of the drug through the jugular veins hence 
avoiding first pass metabolism and promoting an enhanced bioavailability of the drug 
(58). In this way, lower doses of the drug substance may be enough to achieve the 
same therapeutic effect. This also allows a faster onset of action (68); 
- The treatment can be terminated at any time, if required by removal of the chewing 
gum from the mouth (61); 
- MCG have some advantageous characteristics that contribute to the increase of 
patient compliance, such as stress and tension relief, refreshing the breath, cleaning 
the teeth after meals and reduction of dryness in the mouth by stimulating salivary 
secretion (60).  
 
Unfortunately there are also some limitations associated with MCGs and its components, 
which may affect the performance and viability of the drug delivery system. These limitations 
are enumerated below:  
- May induce some allergic reactions due to the use of flavoring agents, colorants and 
other excipients (60).  
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- Aspartame, a sweetening agent used in most of chewing gums, can enhance the risk 
of diabetes, neurological disorder, birth defects and for long users can enhance the 
risk of cancer and increase the release of mercury vapor from dental amalgam filling 
(60). Another sweetening agent, sorbitol, can cause diarrhea and flatulence (58) 
- Chewing gum may adhere to different degrees to enamel dentures and fillers (61).  
- The masticatory act involves a set of muscles, salivary glands and cartilage which 
when damaged may cause serious problems (60).  
The unnecessary damage of the cartilage that acts as a shock absorber in the jaw joints leads 
to pain and discomfort for a lifetime. The production of steady stream of saliva for chewing 
gum is a waste of energy and resources that otherwise could be used for essential metabolic 
activities. Unnecessary damage of facial muscles located to the temples can contribute to 
chronic intermittent headache, due to the pressure on the nerves. But there is a low 
probability of this kind of injuries take place or they may be highly avoidable, since the 
patient chews the MCG up to 30 minutes (58, 60, 61). 
 
 
3.1.5. In Vitro and In Vivo Evaluation 
As any other drug delivery system, there the need for controlling the variables that can 
influence the performance of MCG, in order to achieve acceptable organoleptic and 
technological properties (66). There are some prerequisites that need to be fulfilled in order 
to achieve patients’ compliance such as a pleasant and long-lasting taste, also an optimal 
chewing volume, anti-adherent properties to the teeth, and acceptable pharmaceutical 
properties, such as fast and complete drug release from the formulation (66). Two different 
types of tests are performed to determine the drug product characteristics: quality control 
tests during manufacture and for market release as well as other performance tests (58, 60, 
61).  
3.1.4. 1. Quality Control Studies  
Medicated Chewing Gums have to comply with the requirements of the  Eur. Ph. (60): 
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1. Uniformity of Content. MCG with content of 2 mg or less than 2 % of the total 
mass of gum must comply with the test A for uniformity of single dose preparations 
(69), unless otherwise prescribed or justified and authorized (58, 60, 61). If the 
formulation has more than one active substance, the requirements apply only for 
those active substances which correspond to the above situation.  
2. Uniformity of Mass. Uncoated MCG and, unless otherwise justified and authorized, 
coated MCG must comply with the test for uniformity of mass of single dose 
preparations (70).  
3. Drug Release from MCG. Drug release evaluation for MCG is completely 
different when compared with conventional drug delivery systems (66), having 
requirements for a specific and particular in vitro apparatus which is able to mimic the 
masticatory movements (67). Below there is the description of two apparatus used 
for testing in vitro drug release from MCG, being both referenced as useful tools for 
these performance tests (55).  
 
3.1.4.2. In Vitro Studies  
Apparatus I. Chewing Gum Apparatus, Compendial – Eur. Ph. 
The Eur. Ph. adopted this chewing apparatus in 2000 (61) and its representation is shown in 
Fig. 3.4. The chewing apparatus comprises a chewing chamber where the medicated chewing 
gum is placed in order to be subject to mechanical forces applied by the two horizontal 
pistons and the vertical piston (tongue) – which work together at a constant speed – that 
mimics the human masticatory act. The tongue operates alternatively with the two 
horizontal pistons and makes sure that the gum is kept in the right place between chews, 
while the horizontal pistons rotate around their own axes in opposite directions after each 
chew so that the gum is subject to maximum chewing (67). The procedure is described in 
Eur. Ph. and the chewing frequency is usually set at 60 cycles/minute (67). 
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Apparatus II. Alternative Chewing Gum Apparatus, Noncompendial – Wennergren  
A noncompendial apparatus for in vitro drug release test from MCG was developed by 
Wennergren (71) and its schematic representation is shown in Fig. 3.5A. The apparatus has 
six chewing modules, being each module a thermostated test cell of glass (71) that contains 
two vertically oriented pistons holding an upper and a lower chewing surface (Fig. 3.5B), 
respectively. The medicated chewing gum is placed in the lower chewing surface and the 
chewing procedure consists of reciprocations of the lower surface in combination with a 
twisting movement of the upper surface that provides mastication of the chewing gum and at 
the same time an adequate agitation of the test medium (60, 71). The upper chewing surface 
is parallel to the central part of the lower one, which has a small brim angled upwards in a 
45 degrees angle so that the lower fraction functions as a small bowls with a flat bottom. 
This helps to prevent the chewing gum from sliding during the mastication process (67). This 
Figure 3.4. Apparatus for the determination of drug release from MCG (67). 
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Figure 3.5. (A) Technical drawing of the noncompendial chewing apparatus – the entire setup 
showed the six chewing modules. (B) Detail of one chewing module (71). 
A 
B 
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apparatus shows satisfactory results for distinct formulations, since the adjustments of 
instrumental settings have a large freedom of choice, being adaptable for distinct drug 
products (71).  
Besides being possible to produce MCG with conventional tablet press, the in vitro evaluation 
is a limiting step for pharmaceutical companies, because it requires specific equipment 
described in the Eur. Ph. (67). It means that if a company aims to develop medicated chewing 
gums, has necessarily to access an apparatus for evaluation of drug release so that it can be 
accepted by the regulatory entities. 
 
3.1.4.3. In Vivo Studies  
In vivo “chew-out” studies are performed in human volunteers in order to evaluate the 
release of active drug substance from Medicated Chewing Gums. In vivo studies are 
important because the dosage form is subject not only to the mechanical stress of chewing 
(that is provided by the apparatus for in vitro studies), but also to the physiological 
phenomena during the masticatory process, such as the increase of salivary secretion, 
variations of salivary pH, swallowing and absorption through the buccal mucosa (64). Those 
physiological phenomena can highly influence the performance of the dosage form as well as 
the amount and rate release of the active drug substance (58). The in vivo methodologies 
described in literature are: release of drug in saliva, dissolution test of residual medicated 
chewing gum, urinary excretion profile of medicated chewing gum and buccal absorption test 
(58, 61, 72). In each of these tests, volunteers are asked to make use of MCG and thereafter 
samples of saliva, residual gum or urine are withdrawn and analyzed with proper methods 
for content of active drug substance (72). Besides the importance of these tests, they are 
actually alternative methods because there are no guidelines available for in vivo performance 
tests for MCG.  
 
Besides all the available in vitro tests and in vivo alternatives for determination of drug release 
from MCGs, it may not be forgotten that pleasant flavor and texture of the gum are crucial 
to the success of formulation. It means that texture studies are also required, and must be 
done in vitro by instruments and also in vivo in human volunteers (61). In vitro texture analysis 
requires an instrument that applies a constant force on the surface of the self-supporting 
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MCG, on the recommendation of the compression probe to have greater surface are than 
the MCG. During the process a deformation curve of the response of MCG to the 
compression is generated, recorded and interpreted. This instrumental analysis test enables 
a variety of textural properties to be evaluated, namely hardness and adhesiveness (61). In 
case of in vivo texture analysis, the volunteers are simply asked to chew the dosage form for 
a particular period of time. Then each volunteer describes his chewing experience in terms 
of the qualities of the MCG, such as product feel, consistency, taste, and total flavor lasting 
time during the masticatory process (61).  
 
 
3.1.6. Market and Regulatory Considerations 
Table 3.2 gives details about marketed products in the form of medicated chewing gums. The 
market of MCG is rich in products used for smoking cessation, alertness enhancers and 
motion sickness removal, as said previously in this monograph. But it does not count with 
many products available. USA is the country where this dosage form is widely disseminated, 
with approximately 50% of the world market for MCG (64). Nonetheless the small number 
of marketed MCG, the market is growing as the technological and pharmaceutical 
knowledge increases and the population is educated for acceptance of this new patient 
centric dosage form.  
Medicated chewing gums are an attractive dosage form because it allows the reformulation 
of drug substances already in the market in other dosage forms that will make a 
differentiation point in pharmaceutical industry and in the upcoming generics competition. 
This novel drug delivery system is an opportunity for product-line extension (60, 64). A brief 
research in literature and in patent databases show that there are many patents filled on 
MCG field (58,61). 
 
 
3.2. Conclusion 
Medicated Chewing Gum is a feasible drug delivery system which shows great patient 
compliance. That is due not only to clinical benefits, and the possibility to act both locally 
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Table 3.2. MCG available in the market (56, 58, 60, 61).  
Name Drug   
Substance 
Aim Commercially  
Available 
Aspergum Aspirin Pain relief North America 
Brain DHA & CCE Enhanced brain activity Japan 
Chooz Calciumcarbonate Stomach acid neutralization USA 
Chroma Slim Cromium Diet USA 
Nicorette Nicotine Smoking cessation Worldwide 
Nicotinell Nicotine Smoking cessation Western Europe, Australia 
Superpep Dimenhydrinate Travel illness Germany, Switzerland 
Endekay Vitamin C Vitamin C General health Middle East, United Kingdom 
Stamil  
Vimatin C 
Vitamin C General health Australia 
Source  
Vitamin C 
Vitamin C General health Australia 
Stay Alert Caffeine Alertness USA 
Café Coffe Caffeine Alertness Japan 
Buzz Gum Guarana Alertness United Kingdom 
Go Gum Guarana Alertness Australia 
Fluorette Fluoride Cariostatic USA 
Vitaflo CHX Chlorhexidine Preventing tooth decay USA 
Travvel Dimenhydrinate Motion sickness USA, Australia 
Trawell Dimenhydrinate Travel illness Italy, Switzerland 
V6 Xylitol 
Prevention of formation of 
dental caries 
United Kingdom 
 
and systemically, but also because MCG are shown to be an attractive, discrete and efficient 
drug delivery system. In spite of that, the potential of MCG has not yet been fully exploited. 
3. Chapter I1. Medicated Chewing Gums 
 
60 
 
Pleasant taste and flavor are crucial for the market success of the formulation. Medicated 
Chewing Gums are intended to be chewed but not swallowed, meaning that they are 
withdrawn from the mouth after the desired effect is achieved or after a predetermined time 
of chewing. This drags the problem of the sticky nature of chewing gum. It is desired to 
develop chewing gums composed in a way that they can be removed from surfaces by 
conventional cleaning methods and technologies (61). It may be promising to incorporate 
biodegradable excipients so that it disappears by means of nature’s own remedies, like 
water, light and bacteria (61). 
Besides MCG being described in a monograph of Eur. Ph., as well as the dissolution 
apparatus for in vitro evaluation of drug release, there is no reference to MCG in USP, nor 
dissolution apparatus for this drug delivery system. Chewing gums with active pharmaceutical 
substances are also mentioned in guidelines for pharmaceutical dosage forms by the 
Committee for Medicinal Products for Human Use. The development of MCG meets high 
quality standards in pharmaceutical industry but requires specific technologies and facilities 
different from those normally used in pharmaceutical industry, involving hot-melt processes, 
which tend to be rare. It makes new gum bases formulations which are compressible, such 
as Health in Gum, available to extend applications of chewing gum and offers a possibility for 
innovation of conventional pharmaceutical companies. Besides the possibility of developing a 
promising new drug delivery system with no requirements for specialized manufacturing 
equipment, regular entities require quality control tests, namely in vitro drug release 
performance tests which require specific apparatus mentioned in Eur. Ph.. In other words, 
pharmaceutical companies are able to manufacture Medicated chewing gums with standard 
tablet compression equipment but need to invest in new equipment in order to be able to 
perform drug release tests.  
 
  
 
 
 
 
 
4. CHAPTER III 
PULSATILE DRUG DELIVERY SYSTEMS 
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4.1. Pulsatile Drug Delivery Systems 
Some diseases that are referenced in Table 4.1 show a predictable circadian rhythm (73 – 
75). In this way, a controlled timing of medication regimens can improve therapeutic 
outcomes in these diseases. It means that a strategic time of administration would allow the 
onset of therapeutic drug concentrations to coincide with the time at which disease 
symptoms / manifestations are more likely to occur (74), thus having higher therapeutic 
efficacy and enhancing patient compliance. In this context, Pulsatile Drug Delivery Systems 
(PDDS) are a type of dosage form that have been developed in close connection with 
emerging chronotherapeutic views (73 – 75).  
PDDS are able to control different crucial variables in drug delivery in such a way that it is 
possible to deliver the right dose of the drug at a specific time and in a specific local (73, 75), 
 
Disease Chronical Behavior Drugs used 
Asthma  Precipitation of attacks during night and at early morning hours 
Antihistamines, β2 
agonists 
Arthritis Pain in the morning. Level of pain increases at night 
NSAIDs, 
Glucocorticoids 
Attention Deficit 
Syndrome 
Increase in DOPA levels in afternoon Methylphenidate 
Cancer 
The blood flow to tumors is threefold greater during each daily 
activity phase of the circadian cycle than during the daily rest phase 
Vinka alkaloids, Taxanes 
Cardiovascular 
Diseases 
Blood pressure is at its lowest during sleep cycle and rises steeply 
during the early morning 
Nitroglycerin, calcium 
channel blockers, ACE 
inhibitors 
Diabetes mellitus Increase in blood sugar level after a meal 
Sulfonylurea, Insulin, 
Biguanide 
Duodenal Ulcer 
Gastric acid secretion is highest at night, while gastric and small 
bowel motility and gastric emptying are all slower at night 
Proton pump inhibitors 
Hypercholesterolemia Cholesterol synthesis is generally higher during night than daylight 
HMG CoA reductase 
inhibitors 
Neurological 
Disorders 
The central pathophysiology of epilepsy and the behavioral 
classification of convulsive events  
MAO-B inhibitors 
Peptic Ulcer Acid secretion is higher in the afternoon and at night H2 blockers 
Table 4.1. Diseases that show a circadian rhythm for pulsatile drug delivery (73 – 75). 
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thus providing spatial and temporal drug delivery. The drug release profiles of such systems 
are characterized by two distinct phases (73 – 75), as depicted in Fig. 4.1. The initial phase 
after the formulation administration is known as lag time and requires a pattern of no drug 
release at all (73), it is the time between the administration of the dosage form and the 
beginning of the drug release (75, 76), and it is followed by a second phase characterized by 
a complete release of the drug within a short period of time (74). Lower lag times are 
intended to deliver the drug in the upper parts of the GIT, while higher lag times are 
desirable for the drug release in the lower portion of the small intestine (76). PDDS may be 
characterized as single pulse systems (Fig. 4.1.A–C) or as multiple pulse systems (Fig. 4.2), 
depending on the function of the dosage form (76). In single pulse systems the drug is 
completely released at once and in a specific region of the GIT after the lag time (73 – 76). 
On the other hand, multiple pulses systems deliver the drug in divided doses in concomitant 
pulses and may be programmed to deliver fractions of the drug in distinct parts of the GIT 
(76). Multiple pulses systems are developed as pellets or minitabs (76) with multiple coating 
layers (77), which may be further converted into tablets or capsules to form a single unit 
dosage form (76). There is also the possibility of developing multiple pulses release 
 
Figure 4.1. Schematic representation of different single pulse drug release profile where (A) is 
sigmoidal release after lag time, (B) is a delayed release after a lag time, (C) is a sustained release 
after a lag time and (D) is an extended release with no lag time. For pulsatile drug delivery systems 
(A, B and C) dark grey represents the initial phase with no release (lag time) and light grey 
represents the second phase of DS release (73 – 76). 
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formulations with different drug substances in each layer, thus with a single dosage form it is 
possible to act in different diseases with distinct times and/or sites of drug release (77). The 
off-release lag time may be adjustable by manipulation of the formulation composition, in 
order to have the best drug release profile for the targeted disease. 
Investigation in academia and industry has been driven in distinct ways to develop the most 
adequate PDDS. In the present time, several are the approaches to pulsatile behavior of 
dosage forms found in literature (see Fig. 4.3). 
 
 
4.1.1.  Classification and Manufacturing Processes 
PDDS can be classified in three categories, as shown in Fig. 4.3: time controlled, stimuli 
induced and externally regulated.  
In those systems the major factor to fine-tune is lag time, and the purpose is to ensure a 
delivery of the drug in the proper local and proper time to achieve optimal therapeutic effect 
and minimal side effects.  
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Figure 4.2. Schematic representation of a multiple pulse drug plasma concentration profile from a 
pellet with multiple containing layers. Adapted from 77.  
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I. Time-Controlled Pulsatile Drug Delivery Systems 
In time-controlled pulsatile drug delivery systems, the release of the drug substance is 
independent from the environmental factors (78). Those systems can be further classified in 
single unit or multiparticulate systems (73, 74, 78) and are mostly formulated as capsules or 
tablets for oral administration.  
 
SINGLE UNIT SYSTEMS 
Capsule based systems. The general design of capsule based systems consists of a water 
insoluble capsule body housing a drug formulation entrapped by a plug that pushes itself out 
of the capsule after contact with the dissolution medium (73) (see Fig. 4.4). The plug is 
responsible for controlling the lag time prior to drug release and that is achieved by 
manipulation of its physical and chemical properties and position (73, 75, 78). The plug may 
be made of different approved excipients and based on its constitution, distinct behaviors are 
expected: the plug being removed after a predetermined lag time due to swelling, erosion or 
Figure 4.3. Schematic representation of approaches for the development of pulsatile drug delivery 
formulations. PDDS can be broadly classified in three major categories (time-controlled release 
systems, stimuli induced release systems and externally regulated systems) (73, 75, 78).   
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dissolution (79). Krögel and Roland (79) reported that an erodible plug is more effective 
than a swelling one, because it is possible that the swollen plug isn’t always ejected as one 
piece, which may compromise drug release. Additionally a tight fit between the plug and the 
impermeable capsule body is mandatory to prevent water penetration and premature drug 
release (79). The drug release rate from the capsular body is then influenced by the inclusion 
of effervescent or disintegrant agents, which are reported to accelerate the process (79). 
The manufacturing procedure to develop such systems is similar to that shown in Fig. 4.5. 
But in this process the capsule was hand filled and the plugs were also placed by hand (79), 
what may turn this method very difficult to scale-up using standard pharmaceutical 
equipment. 
The first capsule based system for pulsatile drug delivery described in literature was 
Pulsincap® system, developed by R. P. Scherer International Corporation (80). This system is 
schematically identical to the one represented on Fig. 4.4: a water-insoluble capsule body 
containing the drug reservoir that is enclosed by a swellable hydrogel plug. Upon contact 
with dissolution medium this plug swells until it is ejected from the capsule body allowing a 
rapid drug release after a lag time (75). 
Osmosis based systems take advantage of osmotic pressure in order to achieve a controlled 
delivery of a certain drug substance (81). The osmotic system consists of a capsular body 
coated with a semipermeable membrane holding the drug formulation, an insoluble plug and 
an osmotically active agent (82). When in contact with the dissolution medium, the 
semipermeable membrane allows water diffusion, what results in an increased inner pressure 
(78). Consequently the insoluble plug is ejected from the capsular body after a lag time and 
the active drug substance is released (78, 81). In osmosis based systems, the release rate of 
drug substances is independent of pH and other physiological parameters, once the 
semipermeable membrane does not allow solute permeation (81). The lag time of an 
osmosis based system may be modulated by the semipermeable membrane thickness (82). 
An example is the Port® system, developed by Therapeutic Research Laboratory Ann Arbor 
(78, 82). The manufacturing process of this system may be similar to that described in Fig. 
4.5, taking into account the differences in the formulation, namely the plug’s characteristics 
and constitution, and the presence of a coating layer. Osmosis based systems are also 
developed as tablets that have at least one delivery orifice, through which the drug is 
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Figure 4.4. Schematic representation of capsule based system (A) and its different stages in drug 
release. When in contact with dissolution medium (B) the water soluble cap dissolves, the plug 
pushes itself out of the capsule body and (C) the drug formulation is released (73, 74, 78).  
Figure 4.5. Schematic diagram of pulsatile capsule based system design, both with compressed plug 
or meltable plug (79).  
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released, an osmotic drug core (optionally containing an osmagent) and a semipermeable 
membrane that allows water diffusion (81). In its simplest design, the elementary osmotic 
pump (EOP), the water influx through the semipermeable membrane is responsible for an 
increased osmotic pressure of core formulation that leads to the drug release (81), see Fig. 
4.6. Osmosis based systems with a delivery orifice may also be available in capsular dosage 
form for the delivery of lipophilic liquid formulations (81). It was not possible to find any 
information regarding the manufacturing process of such drug delivery systems. 
Pulsatile systems with rupturable coating layer (Fig. 4.7A). The release of the drug from these 
systems is dependent on the disintegration rate of the outer rupturable layer. On the other 
 
 
 
 
 
 
 Drug core 
Outer rupturable layer 
Inner swellable layer  
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Drug core 
Erodible coating layer B 
Figure 4.7. Schematic diagram of single unit delivery systems (A) with rupturable layer and (B) 
with erodible layer (74, 78). 
Figure 4.6. Schematic diagram of elementary osmotic pump and its mechanism of drug release (81). 
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hand, the formulation, water permeation and mechanical resistance define the lag time prior 
to drug release (83). The use of effervescent excipients, swelling agents or osmotic agents in 
the inner layer help to achieve the pressure required to the rupture of the coating triggering 
drug release (75). Optimization of the system allows drug release to be obtained at a specific 
time. Sungthongjeen et al (80) developed a tablet consisting in a core coated with an inner 
swelling layer and an outer rupturable layer, following the general manufacturing procedure 
described in Fig. 4.8A. Capsular systems of this type may be manufactured as described in 
Figure 4.8. Schematic diagram of (A) pulsatile tablet with rupturable and swellable layers design 
(80)  and (B) pulsatile capsules with rupturable and swellable layers (84) manufacturing process. 
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Fig. 4.8B (84). In both tablet (80) and capsule (84) the inner layers contain croscarmellose 
sodium and the outer rupturable layers contain ethylcellulose, which is the widest used 
polymer since it ruptures efficiently (85). 
Pulsatile systems with erodible coating layer (Fig. 4.7B), consist on a reservoir core containing 
the drug that is coated with a layer that erodes or dissolves after a specific lag time (78). 
Chronotropic® system and Timeclock® system are both examples of this type of system 
described in literature. Chronotropic® system consists on a core containing the drug that is 
coated with the hydrophilic polymer HPMC, being suitable for both tablets and capsules 
(78). Timeclock® system consists on a solid dosage form, either capsule of tablet, coated 
with an aqueous dispersion to which is added a water-soluble polymer in order to enhance 
adhesion to the core (86). When in contact with aqueous media the coating layers of both 
these systems erode or emulsify after a lag time, releasing the drug. The lag time and the 
onset of action are controlled by the thickness and the viscosity grades of the polymers used 
in the coating layers, and are independent of gastrointestinal motility, pH, enzyme and GRT 
(86). This system can be manufactured using standard pharmaceutical equipment. In case of 
tablets, conventional compression machines may be used as well as drum coaters (80), 
following a procedure similar to that shown in Fig. 4.8A taking into account that there is no 
need for a second coating with the rupturable layer. An alternative way to manufacture this 
dosage forms is by using the press-coating technique, but this method is less reliable for the 
industrial scale manufacturing process due to the necessity of a central placement of the 
core tablet within the press-coated tablet (87). In the case of capsules the manufacturing 
process adopted may be similar to the one depicted in Fig. 4.8B, also taking into account that 
there is no need for a second coating with the rupturable layer. 
 
MULTIPARTICULATE SYSTEMS  
Multiparticulate systems are developed as capsules or tablets containing a large number of 
small sized particles – pellets (88). The basic concept is that the drug substance is released 
by those individual subunits, and the efficiency of the entire dose depends on the quality of 
each subunit as an individual system and all subunits globally (88). This system allows 
blending pellets with distinct composition and/or release patterns (77), once each pellet may 
have its own core drug formulation. Multiparticulate systems share the same basic principles 
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of single unit systems being the drug release rate from pellets dependent on the type of 
disintegration mechanism of coating layers: erosion or dissolution, swelling and rupturing 
(77). Beyond having all the advantages of single unit formulations, multiparticulate systems 
are being developed in order to overcome some of their limitations (77, 88):  
- Improved bioavailability due to a smaller size;  
- Less inter- and intra-subject variability;  
- Smaller risk of dose dumping (it is less probable that any damage will affect all the 
subunits at the same time); 
- Reduced risk of local irritation. 
However there are some drawbacks associated with those systems when compared to 
single unit systems, namely higher costs of production and multiple formulation steps (77).  
Multiparticulate systems may be developed by coating of nonpareil seeds (89), in order to 
overcome the limitations associated with their production by methods that required high 
specialized equipment and technology. Among all the available coating techniques, spray-
coating in a fluid bed drying is the most commonly used, due to the advantages concerning 
time, costs and quality in the process development (89). The layering process is applied both 
for the drug substance load and for the desired coating layers (89). This technique allows the 
development of pulsatile multiparticulate systems with standard pharmaceutical equipment, 
such as tableting machines and capsule filling machines.  
 
II. Stimuli induced pulsatile delivery system 
In stimuli induced pulsatile delivery systems drug release depends on stimuli from the 
biological environment like temperature or any chemical stimuli (83). Those systems 
incorporate polymeric hydrogels that undergo conformational and physical changes by a 
swelling-deswelling behavior in response to biological stimuli, being those changes reversible 
if the triggering stimulus is removed (90).  
Temperature induced systems are constituted by thermo-responsive hydrogels which undergo 
volume changes in response to temperature variations and promote drug release in the 
swollen state (78). Poly(N-isopropylacrylamide) (PNIPA) is the most studied hydrogel for 
temperature-induced drug release (91, 92), having a lower critical solution temperature 
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(LCST) around 32 and 34 ºC in water, that is possible to be adjusted for drug delivery 
purposes (90, 92). The critical solution temperature is the temperature at which complete 
miscibility of two liquids is achieved (90). In case of polymers with LCST, the solubility is 
inversely proportional to temperature, therefore an increase of the temperature above the 
LCST results in a shrinking behavior of the system (90). On the other hand, if the 
temperature decreases below the LCST, the polymer swells and the drug is released (91). It 
was not possible to find on literature any information regarding the manufacturing process of 
this type of pulsatile drug delivery system. 
Chemical stimuli induced systems release the drug in response to changes due to a chemical 
stimulus like pH, glucose blood levels and inflammation, when the polymer is in the swollen 
state (83). Several efforts have been made to develop this type of drug delivery systems. One 
example is a formulation with pH-sensitive polymers with immobilized glucose oxidase for 
modulated insulin delivery in response to variations in glucose blood levels (93), as an 
integrating part of glucose responsive insulin release systems. Taking advantage of the variations 
of pH environments in the GIT, pH sensitive delivery systems have been developed. Polymers 
such as cellulose acetate phthalate, polyacrylates, and sodium carboxymethylcellulose are 
used to achieve pH dependent drug release. By choosing the suitable pH dependent polymer 
it is possible to deliver the drug in a specific location, such as drug release in the small 
intestine by enteric coating (78). It was not possible to find on literature any information 
regarding the manufacturing process of this type of pulsatile drug delivery system.  
 
III. Externally Regulated Pulsatile Delivery Systems 
In externally regulated dosage forms, drug release is achieved by external stimulation such as 
magnetism, ultrasound, electrical effect and irradiation (93). Besides the existence of 
different approaches, the externally regulated pulsatile drug delivery systems are still 
experimental (93). Magnetically induced delivery system was one of the first types of these 
externally regulated pulsatile delivery systems. The incorporation of a magnetic carrier such 
as iron, nickel, magnetite, cobalt, etc. into capsules or tablets is a way to achieve this 
objective (73). Those components will respond to the application of an external magnetic 
field and will slow down the movement of the administered dosage form in the GIT thus 
changing the timing and/or extent of drug absorption in the stomach or in the intestines (83). 
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It was not possible to find on literature any information regarding the manufacturing process 
of this type of pulsatile drug delivery system. 
When the aim is to obtain a colonic-specific release of the drug that can be achieved by 
coating the pulsatile dosage form with an acidic resistant enteric coat layer (75). 
In this chapter the focus is only these types of systems developed for oral drug delivery in 
the form of capsules and/or tablets. But there are more of these types of dosage forms such 
as inflammation induced drug delivery systems and ultrasound induced pulsatile systems that 
are being investigated in the form of implantable capsules, injectable dosage forms, and 
tissues permeation dosage forms (85, 93).  
 
 
4.1.2. Suitable Drugs and Main Excipients Used in Formulation 
According to previous information in this monograph, the suitable drugs to incorporate in 
PDDS formulations are those which are adequate to treat diseases with a predictable 
circadian rhythm. Table 4.I summarizes the type of drug substances used in each of that 
known diseases, in both research and development. Singh et al (94) published a review on 
drugs used in PDDS for cardiovascular diseases, arthritis and asthma, which are summarized 
in Table 4.2. In the case of cardiovascular diseases, those studies were published for 
treatment of hypertension, angina pectoris and myocardial infarction (94), and studies on 
arthritis were published for treatment of arthritis and rheumatoid arthritis (94). But if we 
analyze in more detail the research studies in PDDS we will see that more active ingredients 
are being studied, included in the categories referenced in Table 4.1. For example, 
Krishnaveni et al (87) reported the development of a tablet dosage form containing 
Montelukast Sodium to treat asthma with awakening nightly phenomena, based on a principle 
of drug administration at bedtime and programmed drug release in early morning hours, 
when the symptoms increase.  
Nevertheless, using the most suitable excipients to formulate pulsatile dosage forms is 
crucial to its success. Since there are distinct types of pulsatile system, the excipients have to 
be chosen very carefully to fulfill the formulation requirements and to make the dosage form 
effective. In this way, the selected excipients must go through strong selection criteria and all 
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Table 4.3. Examples of excipients used in formulation of PDDS. 
Table 4.2. Drug substances used in studies to formulate PDDS (87, 94). 
Diseases Type of drugs used 
Drugs substance 
(trials) 
Cardiovascular 
diseases 
Nitroglycerins, calcium chanel 
blockers, ACE inhibitors 
Losartan potassium, metoprolol tartarate, pronanolol 
hydrochloride, lisinopril, atenolol, captopril 
Arthritis NSAIDs, glucocorticoids 
Aceclofenac, flurbiprofen, indomethacin, lornoxicam, 
methotrexate, meloxicam, diclofenac sodium, 
Asthma Antihistamines, β2 agonists 
Montelukast sodium, salbutamol sulphate, terbutaline 
sulphate, theophylline 
Type of system Excipients widely used 
Refe-
rences 
Time 
Controlled 
Single 
Unit 
Capsule based system Plug 
Swelling Polymethacrilates 
78, 79 Erosion 
HPMC, PVA, polyethylene 
oxide (PEO) 
Dissolution  GMO 
Osmosis based system Cellulose acetate coating 73, 78 
Pulsatile 
systems 
Rupturable 
coating 
EC  84 
Erodible 
coating 
HPMC 78 
Multiparticulate 
The excipients used are dependent on the type of 
multiparticulate system.  
77, 88 
Stimuli Induced 
Temperature induced 
PNIPA, poly(N,N-diethylacrylamide), Poly(2- 
carboxyisopropylacrylamide), Poly(N-(l)-1-
hydroxymethyl-propylmethacrylamide) 
90, 92 
Chemical induced 
Cellulose acetate phthalate, polyacrilates, sodium 
carboxymethylcellulose 
73, 90  
Externally Regulated Magnetically induced 
Incorporation of magnetic carrier: iron, nickel, 
magnetite, cobalt 
91 
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relevant properties must be evaluated, as well as interactions between excipients or 
between excipients and drug substances (87). The combination of the drug substance and 
the most appropriate excipients allows the development of the most adequate formulation. 
Table 4.3 enlists some of the excipients used in the distinct types PDDS formulations, 
commercialized or experimental delivery systems.   
 
 
4.1.3. Factors Affecting The Pulsatile Behavior 
The factor with the major impact in pulsatile behavior of dosage forms is the formulation 
variables, which are dependent on the type of pulsatile system considered. Those 
formulation parameters depend on the type of excipients selected, its amount and 
characteristics (90, 87), the hydrogels used, the constitution and thickness of the polymer 
coating layer, the characteristics of the plug, and so on. Once there are distinct types of 
PDDS, for each type, the formulation variables to consider are measured independently 
from the others, being aware of the fact that distinct parameters may interfere with the 
pulsatile behavior of the same dosage form.  
In time-controlled PDDS it is crucial to control the lag time prior to drug release. In this 
way, factors such as thickness and constitution of the coating layer (80, 81, 95), constitution 
and resistance of the capsular plug (79) and permeability of osmotic plug are determinants of 
the pulsatile behavior. In some cases, the quality of the enteric coating is determinant to 
have a delivery of the drug at the target place, and in case of capsular systems, a thin fit 
between the capsular body and the plug is crucial so that water penetration and premature 
drug release are avoided (79).  
The physicochemical properties of the drug substances are also factors that may affect the 
pulsatile behavior of the dosage form. Coughland et al (92) studied the effect of drug 
physicochemical properties on the behavior of PNIPA hydrogels, and the experiments show 
a great influence of drug solubility, size and chemical nature in the physical behavior of the 
hydrogel as well as in the pulsatile drug release pattern. 
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4.1.4. Advantages and Limitations 
There is a wide range of advantages sustaining the development of pulsatile drug delivery 
systems over conventional dosage forms. The advantages are: 
- PDDS are used in chronotherapy for diseases that show circadian rhythms in their 
pathophysiology, allowing the delivery of the right dose at the right time in the right 
place (75, 78, 94). 
- Increased patient compliance. PDDS allow reduction in dose frequency, strength and 
cost thus reducing side effects without changing the therapeutic effect (75, 78, 85, 
94). 
- Prevents the continuous presence on plasma of drugs that produce biological 
tolerance, thus increasing their therapeutic effect (76).  
- Allows site specific drug release at target site of absorption, like the colon, enhancing 
bioavailability and absorption capacity (75, 85, 94). 
- Site targeting enables delivery of poorly bioavailable drugs in an efficient way, and 
protects gastric mucosa from irritating drugs (75, 78, 85). 
- Provide constant drug levels at the site of action and prevent the peak-valley 
fluctuations in blood stream, maintaining plasma drug concentration within the 
therapeutic window (75, 94).  
- Prevention of drug loss by extensive first pass metabolism, because PDDS provide a 
fast drug input that saturates the metabolizing enzymes, thus minimizing the pre-
systemic metabolism (75, 76) 
- Facility to produce combination of dosage forms and ease of combining pellets with 
different compositions or drug release patterns (multiparticulate systems) (88) 
 
Besides all the advantages mentioned, it is essential to elucidate some limitations of pulsatile 
drug delivery systems, in order to understand the restrictions of those systems and the 
pathway that researchers have to draw in order to achieve an optimal dosage form for 
pulsatile delivery of drugs. Those limitations are: 
- Multiple manufacturing steps in case of multiparticulate systems (88) 
- Rupture time cannot be always fine-tuned as it depends on the physicochemical 
properties of the polymer. 
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- In vivo variability in single unit formulations may be observed (94). This means the 
possibility of an unpredictable IVIVC (78).  
 
 
4.1.5. In Vitro and In Vivo Evaluation 
4.1.5.1. In Vitro Studies 
To the best of our knowledge there are no in vitro performance tests described in any 
pharmacopoeia for characterization of pulsatile drug delivery systems. Besides that there are 
some reports in literature which describe alternative ways of evaluating in vitro the 
performance of pulsatile dosage forms, but there is no uniformity in the apparatus used. For 
example, in literature it is possible to find descriptions of in vitro evaluations of pulsatile 
tablets with USP apparatus 1 (95), USP apparatus II (86, 87) and USP apparatus XXIV (80) 
and in vitro evaluation of pulsatile capsules with USP apparatus I (95) and USP apparatus XXIII 
(79). This lack of uniformity between methodologies makes the comparison of the results 
difficult and unreliable. Besides that, tablets are normally evaluated for their physicochemical 
characteristics, such as thickness, friability, hardness and drug content uniformity (87), as 
well as for interactions between components of the dosage form by Fourier transform 
infrared (FTIR) spectroscopy (87) and gamma-scintigraphic studies (86, 87).  
4.1.5.2. In Vivo Studies 
To the best of our knowledge there are no guidelines for in vivo performance tests. Besides 
that literature reports one in vivo study by gamma-scintigraphy in three distinct groups of 
human volunteers that was clinically approved (86).  
Besides the importance of these tests they are actually alternative methods because there 
are no guidelines available for both in vitro and in vivo performance tests for PDDS.  
 
 
4.1.6. Market and Regulatory Considerations 
Some pulsatile technologies and products are already on the market and some examples can 
be found on Table 4.4. Elan Corporation is the leader in terms of number of marketed 
technologies and the multiparticulate systems are the most widely available (85). In spite of 
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that, the market of PDDS in general does not count with many products. Literature reports 
an extensive number of studies and research papers on PDDS are available (74, 76), but 
many investigations are limited to the laboratory scale instead of reaching the marketbecause 
it is much easier to manufacture a small-scale batch in the laboratory than a large-scale batch 
in industry. Nonetheless, as technological and pharmaceutical knowledge increases, the 
number of marketed PDDS is growing. 
 
 
4.2. Conclusion 
A chronodelivery system, based on biological rhythms, is a state-of-art technology for drug 
delivery. The greatest advantage of this delivery system is the possibility to release the drug 
according to the symptom demands of each disease, thus reducing the risk of drug 
resistance.  
Technology Mechanism Marketed Products Company References 
CODAS™ Multiparticular system Verelan® PM Elan Corp. 75, 77 
DIFFUCAPS® Multiparticular system Innopran® XL, Zofran, AMRIX® Eurand’s Corp 75, 77 
GEOCLOCK™ Single unit tablets Lodotra® Skyepharma 75 
GEOMATRIX™ Multi-layered tablet 
Madopar™ DR, Paxil CR™, Zyflo 
CR™, Xatral™, Sular™, 
Coruno™, Diclofenac- 
ratiopharm™ uno, Requip™ 
Once-a-day 
Skyepharma 96 
IPDAS® 
High density 
multiparticulate tablet 
Naprelan® Elan Corp. 75, 85 
OROS Osmotic mechanism 
Procardia XL®, Ditropan XL®, 
Concerta®, Covera-HS®, 
Invega™ 
ALZA Corp. 75, 85 
PULSYS™ 
Timme-Controlled 
system 
Moxatag® 
MiddleBrook  
Pharmaceuticals 
75, 77 
SODAS® Multiparticular system 
Avinza®, Ritalin® LA, Focalin® XR, 
Luvox® CR 
Elan Corp. 73, 97 
Table 4.4. Pulsatile technologies available in the market. 
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Besides being a promising drug delivery system, it is not described in any pharmacopoeia and 
there are no guidelines regarding suitable performance tests for these formulations. For this 
reason, there is the need to define standard methods for the characterization of the dosage 
form. It is also important that researchers understand the limitations of those systems and 
find ways to overcome them. For example, the efficiency of the dosage form is dependent on 
formulation factors such as the core characteristics, the polymers used in coating layers and 
their thickness in case of tablets, and on the plug characteristics and capsular body 
constitution used in case of capsules. All these parameters may be adjusted in order to 
achieve the desired lag time, which is the major factor encompassing the success of the 
dosage form. The major challenge is the understanding of the influence of the biological 
environment on the release performance of pulsatile drug delivery systems in order to 
develop simple systems based on approved excipients with a good IVIVC. 
Literature describes several attempts made by different researchers to achieve the goal of 
developing the best formulation of this delivery system, and there are inclusively some 
patents registered on this field. Nonetheless, pulsatile drug delivery systems are still largely 
experimental (particularly stimuli induced and externally regulated). Although there is many 
research in this field, there are few products in the market. 
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5.1. Self-Microemulsifying Drug Delivery Systems 
A pronounced parcel of new drug candidates are poorly water soluble substances and their 
oral delivery tend to be challenging  due to their low bioavailability, high inter and intra 
subject variability and lack of dose linearity (98). For this reason, the development of lipid 
based formulations for the oral delivery of lipophilic drug candidates in order to enhance 
their bioavailability have gained importance in pharmaceutical industry (98). Great attention 
has been given in particular to microemulsion based formulations (99, 100) due to the 
capacity of microemulsions to behave as a reservoir for drug substances (99). 
Microemulsions are thermodynamically stable and optically isotropic solutions, but are not 
able to be encapsulated due to their water content (98 – 100), hence, Self-Microemulsifying 
Drug Delivery Systems (SMEDDS) are being developed (98, 100, 101). These consist 
essentially on isotropic mixtures of oil, surfactant, co-surfactant and drug substance which, 
when in contact with an aqueous medium such as GIT, tend to spontaneously form 
microemulsions (98). These dosage forms bring about some advantages namely enhanced 
drug solubilization, faster release rates and improved absorption due not only to the already 
dissolved form of the drugs substance in the formulation but also to the resulting small 
droplets size of less than 50 nm that provide a large interfacial surface area for drug 
absorption (98, 102, 103). But SMEDDS have also some disadvantages regarding the 
manufacturing processes and high production costs, possibility of interaction between the 
formulation and the capsule shell, the possibility of irreversible precipitation of drugs and 
excipients, special storage requirements (100, 101), and few choices of final dosage forms 
since they are presented only as soft or hard gelatin capsules (98). These disadvantages may 
be overcomed by the development of Solid Self-Microemulsifying Drug Delivery Systems (S-
SMEDDS) (100, 101). Generally these dosage forms are prepared by incorporation of the 
liquid self-microemulsifying excipients into powders by different solidification techniques, and 
may then be encapsulated or compressed to make capsules or tablets, respectively (100, 
101). S-SMEDDS combine the advantages of liquid self-emulsifying formulations and the 
advantages of solid dosage forms (100, 101) and are promising dosage forms for the delivery 
of lipophilic drug substances. 
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5.1.1. Manufacturing Processes 
In the process of developing S-SMEDDS, the first step is to achieve the desired liquid 
SMEDDS formulation and the next step is to apply to that formulation a solidification 
technique that allows a liquid-to-solid transformation (99, 100).  
The schematic diagram of SMEDDS manufacturing process is represented in Fig. 5.1. The 
different components of the formulation are placed in the same recipient and are mixed by 
gentle stirring and by harsh mixing (such as vortex mixing (104) or sonication (105)) and are 
heated on a magnetic stirrer until all drug substance is completely dissolved. The final 
mixture is a SMEDDS that is stored at room temperature until further use. That further use 
in this case may be, as represented in Fig. 5.1, encapsulation to form a capsular dosage form 
of SMEDDS (101, 106) or solidification to form S-SMEDDS. 
Literature reports a variety of different reliable solidification techniques to transform 
SMEDDS in S-SMEDDS (100, 101): 
1. Spray Drying 
The fluxogram of S-SMEDDS manufacturing process by spray drying is represented in Fig. 
5.2. Essentially SMEDDS are mixed with a solid carrier (such as dextran 40 (107) and 
maltodextrin (108)) under continuous stirring. The mixture is heated during the necessary 
time until an homogeneous dispersion is obtained, that is further placed in a spray dryer 
(107, 108) to obtain a dry powder able to be encapsulated or compressed into a tablet (100, 
101). As the drying process takes place, the load (liquid SMEDDS) adsorbs onto the surface 
of the carrier and forms granular particles with entrapped drug substance (108). There are 
some parameters that influence the spray-drying process performance, namely the airflow 
pattern and the temperature (109) that must be optimized accordingly to the drying 
characteristics of the product and powder specification (100, 101). 
Spray drying is one of the most widely used techniques for microencapsulation with standard 
pharmaceutical equipment and enables efficient scale-up (108), and solid SMEDDS prepared 
by this technique are described to preserve the emulsifying properties of liquid SMEDDS 
(107, 108).  
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Capsule 
SMEDDS 
Mixing  
Encapsulation 
Drug Substance 
Oil 
Surfactant 
Co-Surfactant 
Figure 5.1. Schematic diagram of SMEDDS manufacturing process (98, 104, 105).  
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Figure 5.2. Schematic diagram of S- 
-SMEDDS manufacturing process by spray 
drying technique (107, 108).  
Figure 5.3. Schematic diagram of S-SMEDDS 
manufacturing process by adsorption to a solid 
carrier technique (110, 111).  
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2. Adsorption to Solid Carrier 
The manufacturing process of S-SMEDDS by adsorption to a solid carrier is represented in 
Fig. 5.3. Essentially SMEDDS and one or more solid carriers (such as microcrystalline 
cellulose (MCC) (110) and colloidal silicon dioxide (110, 111)) are mixed in a blender and 
then dried to a free flowing powder (110, 111) able to be encapsulated or blended with 
suitable excipients prior to compression into tablets (100, 101, 110). The solid carriers may 
be materials that provide high surface area with good disintegration characteristics (110) and 
the liquid SMEDDS adsorb to them, forming free flowing granular particles (111). S-SMEDDS 
prepared by this technique are described to preserve the emulsifying properties of liquid 
SMEDDS (110, 111). This solidification technique seems to be easy and effective, but there 
are some constraints that may affect its success, namely problems related to the 
compression technique and the final tablet, such as the possibility of exudation, sticking and 
hardness issues, and the need of a large quantity of solid carrier to adsorb the liquid 
formulation that leads to a final dosage form with a large volume (102).  
 
3. Melt Granulation 
Melt granulation is a technique in which powder agglomeration is achieved through the 
addition of either a molten binder or a solid binder which melts at relatively low 
temperatures during the process (100, 101, 112), acting like a liquid binder between particles 
(112). This solidification technique consists on the combination of three phases (112, 113): 
I. Wetting and Nucleation Step. In this step the binder is blended with the powder bed 
and some liquid bridges are formed, leading to the formation of small agglomerates, upon 
heating. There are two main mechanisms proposed for the nucleation step, taking into 
account the relative particle size of different components: a) immersion and b) distribution.  
Nucleation by immersion takes place when the molten binder droplets are bigger than the 
fine solid particles, and the mechanism consists on deposition of fine solid particles onto the 
surface of molten binder droplets, as seen in Fig. 5.4A. On the other hand, nucleation by 
distribution leads to the distribution of the molten binding liquid onto the surfaces of fine 
solid particles, as seen in Fig. 5.4B, provided by the collision between wetted particles. 
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II. Coalescence step. In this step a successful fusion of nuclei is observed, which is 
promoted by surface liquid of nuclei. That surface liquid is essential for enabling the 
deformation of nuclei surface for coalescent, as well as for promoting the rounding of 
granulation, since it imparts plasticity to the nuclei.   
III. Attrition-breakage step. This step refers to the phenomenon of granulation 
fragmentation. The solidification occurs by train cooling to ambient temperature, excluding 
the need for drying in a tumbling process. 
Some requirements must be fulfilled concerning melt granulation technique. Namely, the 
meltable binder must be added in a proportion of 10 – 30 % w/w of fine solid particles and 
must be solid at room temperature and must have a melting point within the range 40 – 100 
ºC, while the melting point of fine solid particles must be at least 20ºC higher than that of 
the maximum processing temperature (112, 113). There are hydrophobic meltable binders, 
which are used for prolonged-release formulation (112), such as stearic acid, cetyl and 
stearyl alcohol and various waxes, and hydrophilic meltable binders, which are used for 
immediate-release formulations (112), such as polyoxyl stearates and PEG (112, 113). In this 
technique, there is no requirement for solvent use and the drying process is not necessary, 
thus fewer process steps are required, making melt granulation advantageous over other 
conventional granulation methods (112, 113).  
A 
Heating 
Melting 
+ 
Non-Meltable 
material 
Meltable 
material 
Immersion 
Figure 5.4. Nucleation step in melt granulation solidification technique. A) Nucleation by 
immersion process and B) nucleation by distribution process (112, 113). 
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Gupta et al (114) used melt granulation process to absorb lipids, surfactants and drugs onto 
solid neutral carriers. Pellets produced by this technique are able to be compressed into 
tablets (114).  
 
4. Melt Extrusion/ Extrusion Spheronization 
The manufacturing steps of S-SMEDDS by melt extrusion/extrusion spheronization 
technique is represented in Fig. 5.5. Essentially SMEDDS are mixed with water to obtain an 
o/w emulsion that is added to a dry powder of other excipients, and mixed until a wet mass 
is obtained (115 – 117). Then takes place the extrusion process, in which the wet mass is 
forced through the extruder under controlled conditions, forming spaghetti-like extrudates 
 
Figure 5.5. Schematic diagram of S-SMEDDS manufacturing process by melt extrusion/extrusion 
spheronization technique (115 – 117). 
Other excipients 
SMEDDS + 
water 
Wet mass   
S-SMEDDS pellets   
Encapsulation Compression 
S-SMEDDS 
Capsule 
S-SMEDDS 
Tablet  
Extrusion    
Spheronization 
Mixing   
5. Chapter IV. Self-Microemulsifying Drug Delivery Systems 
 
88 
 
(101, 115, 117). Those are then subject to a spheronization process and broken until 
uniformly sized spheroids are formed (pellets) (116 – 118), which are able to be 
encapsulated or blended with suitable excipients prior to compression into tablets (117).  
This solidification technique is the most reliable for pellet production, due to its capacity to 
incorporate high amounts of drug substance as well as content uniformity, without 
producing excessively large particles (100, 101, 117). The water content is determinant for 
establishment of disintegration time of pellets (100, 101). Since MCC has the capacity to 
absorb water during the process and also to increase the rheological properties of the wet 
masses, it is considered as an essential excipient for successful extrusion/spheronization 
technique (115). But this manufacturing process is not suitable for application in conventional 
pharmaceutical companies, since it requires sophisticated specific equipment usually not 
available. 
 
 
5.1.2. Suitable Drugs and Main Excipients Used in Formulation 
The main formulation components of SMEDDS and S-SMEDDS are the drug substance, oil, 
surfactant and co-surfactant (92, 100). Lipids may affect the bioavailability of the drug 
substance, by changing its biopharmaceutical properties (101), and the solubility of the 
lipophilic DS in lipid excipients may promote the entire dose of the drug to be administered 
in a single dosage unit (98, 100). Thus the selection of oil, surfactant and co-surfactant may 
be based on the solubility of drug substance and the preparation of pseudo ternary phase 
diagrams (100). Some parameters may be considered when developing lipid formulations, 
namely Log P value (values higher than 4 are desired, so that good solvent capacities of drug 
are achieved (101)), and physicochemical characteristics such as melting point and dose (low 
melting point and low dose are desired) (98, 100). The melting point is an indicator of the 
lipid characteristics, as it increases with fatty acid chain length and decreases with its 
unsaturation level (118). Table 5.1 enlists the main excipients used in solid SMEDDS.  
As said previously, SMEDDS are ideally used to increase oral bioavailability of low solubility 
drugs. Thus drugs from Biopharmaceutical Classification System (BCS) class II and class IV, 
which have poor water solubility, are preferably used (98, 100, 120), see Fig. 5.6. The 
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Table 5.1. Example of some excipients used in SMEDDS formulation (98, 100, 121).  
 
Excipient Examples 
Oil 
LCTs Olive oil, Corn oil, Soybean oil, Castor oil 
MCTs 
Miglyol 80, Miglyol 812, Captex 255, Captex 200, 
Tricaprylin 
Fatty Acids Oleic acid, Palmitic acid 
Mono- and Di-
Glycerides 
Capmul MCM, Capmul GMO 
Surfactant 
Tweens, Spans, Cremophore RH40, Labrafil 1944 CS, Labrafil M 2125, 
Labrafac lipophilel 349 WL, Labrasol, Lauroglycol 90, Capryol 90, Peceol 
Co-Surfactant 
Alcohols & 
polyols 
Ethanol, isopropanol, butanol, benzyl alcohol, ethylene 
glycol, propylene glycol, butanediols, glycerol, 
pentaerythritol, sorbitol, mannitol, transcutol, dimethyl 
isosorbide, propylene glycol, HPMC 
Esters 
Ethyl propionate tributyl, citrate, acetyl triethyl citrate, 
acetyl tributyl citrate, ethylene oleate, ethyl caprylate, 
ethyl butyrate, triacetin, propylene glycol mono- and 
di-acetate, ε-caprolactone, δ-valerolactone, β-
butyrolactone 
Esters of 
Propylene glycol 
Tetra hydrofuryl alcohol, PEG ether (glycofural) 
Amides 
Pyrrolidone, 2-piperidone, caprolactam,  
N-alkypyrrolidone, N-alkylpiperidone,  
N-alkylcaprolactam, dimethylacetamide, polyvinil 
Co-Solvent Etanol, propylene glycol, PEG  
Consistency Builders Tragacanth, Cetyl alcohol, Stearic acid, Beeswax 
Polymers HPMC, EC 
 
 
difference is that BCS class II drugs are highly permeable, while class IV drugs are poorly 
permeable (120). Drugs like ontazolast, simvastatin, danazol, vitamin E, tocotrienols and 
itraconazole which belong to BCS class II are strong candidates for SMEDDS formulation 
(121). Taking into account previous information, drug substances with high melting point 
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having low Log P values are not suitable for SMEDDS formulation.  
The oil represents one of the major components in the SMEDDS formulation. This is due to 
the ability to solubilize the necessary dose of the lipophilic drug substance, to assist self-
emulsification process and to improve absorption of drug from the GIT depending on the 
molecular nature of the triglyceride (98). Long chain triglycerides (LCTs) and medium chain 
triglycerides (MTCs) with distinct grades of saturation have been used in SMEDDS 
formulation (98, 121).  
A surfactant is an agent with amphiphilic nature which comprises two parts with distinct 
affinities for the solvents: one shows affinity to polar solvents and the other to non-polar 
solvents (98). Surfactants are used in a range of 30 – 60% of formulation in order to increase 
stability of the formulation and may have high Hydrophilic-Lipophilic Balance (HLB), so that it 
can assist immediate formation of microemulsion in the aqueous media (121). HLB is an 
indicator of the behavior that a surfactant is expected to have, and it measures the 
proportion between the weight percentages of the lipophilic and hydrophilic parts of the 
surfactant molecule (122). To form o/w emulsions the surfactant may have an HLB ranged 
8–18, once hydrophilic molecules are indicated to have high values of HLB (122). The co-
surfactant is used to reduce the oil and water interfacial tension and to allow the 
spontaneous microemulsification process (98, 121). Generally, hydrophobic co-surfactants 
with high values of HLB, in range 10 – 14, are used (98, 121).  
Figure 5.6. Biopharmaceutical Classification System. Adapted from 119. 
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The co-solvent has the purpose to assist the dispersion process and to aid solubilization of 
the drug (98, 123) and it also allows to decrease the amount of surfactant in the formulation 
(123). The consistency builders are incorporated in formulation to modify the stability of the 
microemulsion (98, 121). Inert polymers are also used due to their ability to form a matrix 
and are used in a range 5 – 40% of composition relative to the weight (98, 121).  
As already mentioned, it is crucial to develop a pseudo ternary phase diagram in order to 
determine the concentration range of all main excipients that will yield microemulsions (98, 
100). Each coordinate of the diagram represents different phases of the mixture, namely 
aqueous phase, oil phase and surfactant:co-surfactant mixture (Smix) at fixed weight ratios 
(98). Pseudo ternary phase diagrams are developed using the water titration method (100). 
It consists on the dilution of mixtures containing Smix and oil with water phase added 
dropwise, while the mixture is homogenized under constant stirring (124). The 
microemulsion state is registered when the mixture is transparent (99, 100, 124). Then the 
distinct ratios of formulation components are chosen based on the boundary conditions of 
the pseudo ternary phase diagram and the amount of drug is added to those boundary 
formulations, optimizing the self-microemulsifying formulation (100). Figure 5.7 represents an 
example of a Pseudoternary Phase Diagram, and the grey area represents the microemulsion 
region.  
Water 
Smix 
Oil 
Figure 5.7. Example of a Pseudoternary Phase Diagram. The grey area represents the 
microemulsion region. Adapted from 110. 
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5.1.3. Factors Affecting SMEDDS Efficiency 
The major factors affecting the efficiency of S-SMEDDS and SMEDDS are mainly the same: 
1. Nature and dose of drug substance. As already mentioned, the characteristics of 
drug substance play an important role in efficiency of SMEDDS. Drug substances 
administered at high doses are not suitable to be incorporated into SMEDDS, except if they 
have great solubility in any of the components of the formulation, especially in lipid phase 
(98, 125). Also drug substances which show limited solubility both in water and oil, typically 
having log P values around 2, are not suitable to incorporate in SMEDDS (98, 125). On the 
contrary, drug substances with a log P around 4 are feasible candidates for self-
microemulsifying formulations (101).   
2. Solubility of drug substance in the oily phase. It is crucial that SMEDDS 
maintain the drug substance in their solubilized form which in turn is greatly dependent on 
its solubility in the selected oily phase (98, 125). There may exist a risk of precipitation when 
surfactant or co-surfactant greatly contribute to the solubilization of drug substance, once 
dilution of SMEDDS leads to a decrease of solvent capacity of such excipients (98, 125). This 
make equilibrium solubility studies important for the assessment of the possibility of 
precipitation of the DS in the GIT (98, 125). 
3. Polarity of the lipid phase. Polarity of the lipid phase influences at a high level the 
release of drug substance from the microemulsion (98, 125). The polarity is an indicator of 
the affinity of drug towards solvent, oil or water and the type of forces involved (98). The 
main factors affecting the polarity of lipid droplets are the HLB, the chain length, the degree 
of unsaturation of the fatty acid, and the molecular weight of the lipophilic portion (98). A 
high polarity of the lipid phase will promote a rapid release of the drug into the aqueous 
phase (98), while it is desirable that the drug substance shows low crystallization rates in 
order to have high concentrations of drug substance in solution (125).  
4. Charge of the emulsion droplets. Absorptive cells are negatively charged when 
compared to the mucosal solution in the lumen (98). As so, positively charged 
microemulsions will improve absorption of the DS in the GIT, because they undergo 
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electrostatic interactions with the mucosal surface, enhancing the bioavailability of drug 
substance (98).  
When applying a solidification technique in order to achieve S-SMEDDS, it is also important 
to consider the factors that may affect the efficiency of that conversion to the final solid 
formulation. For example the choice of solid carrier in case of adsorption to solid carrier or 
spray-drying technique is crucial to achieve an appropriate S-SMEDDS. It means that the 
success of the solidification technique will influence the performance of the final solid 
lipophilic dosage form.  
In order to achieve the best and more efficient formulation, each factor should be evaluated 
having in mind the dependency on the others. 
 
 
5.1.4. Advantages and Limitations 
There are some advantages encompassing the development of S-SMEDDS, since they 
combine the advantages of liquid dosage forms with the advantages of solid dosage forms.  
The advantages of liquid SMEDDS are as follows: 
- Enhancement of bioavailability of lipophilic drugs by providing an increased solubility 
in GIT (98, 100). In this way, these dosage forms may improve their rate and extent 
of absorption (100).  
- Food does not negatively affect drug absorption from SMEDDS, otherwise the 
lipophilic fatty content from diet aids absorption (126).  
Additionally, the advantages of solid SMEDDS over liquid SMEDDS are as follows: 
- Can be filled into hard gelatin capsules and may even be incorporated into other solid 
dosage forms such as tablets (100). This is translated into lower production costs, 
convenience of process control and higher stability and reproducibility, when 
compared to soft gelatin capsules dosage forms (100).  
- Spontaneously form microemulsions once in contact with dissolution environment 
(100). 
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There are also some limitations. S-SMEDDS share all the limitations registered for liquid-
SMEDDS: 
- It may register chemical instability of drug substances (98) in what concerns solubility 
and precipitation of drug in GIT (126). 
- Surfactants are used at high quantities, and these large amounts may irritate the GIT 
(98). 
- Volatile co-solvents may migrate into the shells of soft and hard gelatin capsules, what 
leads to the precipitation of the drug substance (98). 
- Lack of good predicative in vitro models for lipid formulations (126). 
- Possibility of lipid degradation by oxidation processes (126). 
 
 
5.1.5. In Vitro and In Vivo Evaluation 
5.1.5.1. In Vitro Studies 
To the best of our knowledge there are no performance tests described in any 
pharmacopoeia for the evaluation of SMEDDS or S-SMEDDS. Besides that there are some 
reports in literature which describe alternative ways of evaluating in vitro the performance of 
S-SMEDDS dosage forms, but there is no uniformity in the apparatus used. For example, in 
literature it is possible to find descriptions of in vitro evaluations of S-SMEDDS with USP 
apparatus II (108, 110, 111) and with the paddle method (107, 109). This lack of uniformity 
between methodologies makes the comparison of the results difficult and unreliable. Besides 
that, S-SMEDDS powders are normally evaluated for their morphological characteristics by 
Scanning Electron Microscopy (107–111) and for the physical state of active drug substance 
by Differential Scanning Calorimetry (107, 108, 110) and X-Ray powder diffraction (107, 108, 
110, 111). The interaction and compatibility between components of the dosage form may 
be evaluated by FTIR spectroscopy (116).  
5.1.5.2. In Vivo Studies 
To the best of our knowledge there are no guidelines for in vivo performance tests. Besides 
that literature reports in vivo studies with animals that were approved by Ethical Committees 
(107, 111, 116).  
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Besides the importance of these tests they are actually alternative methods because there 
are no guidelines available for both in vitro and in vivo performance tests for SMEDDS nor S-
SMEDDS.  
 
 
5.1.5. Market and Regulatory Considerations 
To the best of our knowledge, there are no S-SMEDDS already available in the market. But 
several studies are being conducted regarding the preparation and characterization of these 
solid dosage forms, and a few are related to the development and preparation techniques of 
dosage forms (101). There are many patents concerning SMEDDS and other lipid 
formulations (98). But besides all the advantages mentioned for those dosage forms and the 
many studies that are carried out, there are very few SMEDDS products available on the 
pharmaceutical market, being most of the lipid marketed products Self-Emulsifying Drug 
Delivery Systems (SEDDS), and these examples can be found in Table 5.2. Abbott and Roche 
are the leaders in terms of lipid marketed products. Nonetheless the number of SMEDDS 
dosage forms is low, it may be growing as technological and pharmaceutical knowledge 
increases. 
SEDDS differ from SMEDDS by producing turbid emulsions with higher droplet size (ranged 
100 – 300 nm), by having higher concentration of oil (40 – 80 %) and by using surfactants 
with HLB>12 (98).  
 
 
5.2. Conclusion 
SMEDDS are promising dosage forms which are developed to deliver lipophilic drug 
candidates by the oral route. SMEDDS deliver the drug dissolved in microemulsions, thus 
increasing their bioavailability, since they are already available for absorption when in their 
site of action. These drug delivery systems are presented either as soft or hard gelatin 
capsules, showing a reduced spectrum of dosage forms available. As an alternative to liquid 
SMEDDS, S-SMEDDS combine all the advantages of liquid formulations with the advantages 
of solid dosage forms. For this reason, S-SMEDDS are highly promising candidates to deliver  
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Table 5.2. Some examples of marketed SEEDS/SMEDDS products (98, 127). 
 
 
 
 
 
 
Trade 
Name 
Drug 
Substance 
Formula-
tion type 
BCS Class 
of DS 
Dosage Form 
Company 
Name 
Accutane Isotretinoin SEDDS II (128) 
Soft gelatin 
capsule 
Roche 
Agenerase Amprenavir SEDDS II (129) 
Soft gelatin 
capsule 
GlaxoSmithK
line 
Aptivus Tipranavir SEDDS - 
Soft gelatin 
capsule 
Boehringer 
Ingelheim 
Fortovase Saquinavir SEDDS IV (130) 
Soft gelatin 
capsule 
Roche 
Gengraf Cyclosporine A SEDDS IV (130) 
Soft gelatin 
capsule 
Abbott 
Kaletra 
Lopinavir and 
Ritonavir 
SEDDS 
IV (131) and  
IV (130) 
Soft gelatin 
capsule 
Abbott 
Lipirex Fenofibrate SEDDS II (104) 
Hard gelatin 
capsule 
Genus 
Norvir Ritonavir SEDDS IV 
Soft gelatin 
capsule 
Abbott 
Panimum 
bioral 
Cyclosporine SEDDS II (132) 
Hard gelatin 
capsule 
Panacea 
Biotech 
Rocaltrol Calcitriol SEDDS - 
Soft gelatin 
capsule 
Roche 
Sandimmune 
Cyclosporine A 
SEDDS 
IV (130) 
Soft gelatin 
capsule 
Novartis 
Neoral SMEDDS 
Vesanoid Tretinoin SEDDS - 
Soft gelatin 
capsule 
Roche 
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poorly water soluble drugs. Solid formulations incorporate the liquid components of 
SMEDDS in solid powders that are filled into capsules or compressed into tablets, carrying 
the advantages of more flexibility on dosage forms, reduced production costs, improved 
stability and enhanced patient compliance.   
Besides being a promising drug delivery system, there are no guidelines regarding the 
suitable performance tests for these formulations, making results difficult to be compared. 
For this reason, there are no defined standard methods for the characterization of the 
dosage form. It is also important to understand the factors that may influence the efficiency 
of SMEDDS and S-SMEDDS, in order to achieve the most proficient lipid formulation.  
Although there is many research in this field, there are few products in the market regarding 
SMEDDS and none regarding S-SMEDDS.  
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All over the years significant progress has been made in pharmaceutical area, since patient 
centered drug design has been widely exploited. New Drug Delivery Systems are becoming 
available to overcome the limitations of conventional drug delivery systems, and patients 
have benefited from that progress through the accessibility to several and important 
medicines that improve therapeutic outcomes.  
Even though the oral route is the most commonly used for drug administration it is still 
possible and important to innovate in oral dosage forms.  
It is important to retain the idea that the drug substance must be released from the dosage 
form at a predetermined rate, dissolve in the gastrointestinal fluids, and maintain sufficient 
gastrointestinal residence time. The presented NDDS in this monograph are being exploited 
and developed aiming to provide more efficient drug absorption as well as enhanced oral 
bioavailability of drug substances, parameters which increase patient compliance. 
In order to improve therapeutic outcomes some important conclusions can be drawn from 
this monograph: 
1) In order to improve the efficacy and safety profile of each drug substance it is very 
important the choice of the route of drug administration and the type of dosage 
form. 
2) The success of the development of a formulation depends on the careful selection of 
the excipients, pre-formulation studies and the choice of the in vitro characterization 
tests that should allow the best possible correlation with the in vivo behavior.  
3) In order to develop novel dosage forms with high probability to reach the market for 
the benefit of patients it is very important to: select excipients approved for the 
route of drug administration, to know the regulatory requirements for each 
pharmaceutical dosage forms, to develop scalable manufacturing processes (cost-
effective, with small number of steps and processes that can be conducted in 
equipment available in the pharma industry) and to develop medicines that address 
unmet medical needs. 
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